The Life Sciences Report

Rocket Doctor AI Secures California Network Deal Reaching 60M Consumers

Thu, 20 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/20/2026

Rocket Doctor AI enters a major provider network agreement in California covering 60 million consumers across multiple lines including workers compensation and Medicare. Learn the key details and next steps for investors.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) has secured a broad strategic provider network agreement in California that opens access to more than 60 million consumers through a single relationship. The deal, effective July 1, 2026, covers primary care, complementary services, workers' compensation, auto medical, and Medicare Advantage channels and automatically renews each year.

This agreement stands out because it connects Rocket Doctor to upstream insurers, employer health plans, and other organizations through one national network partner instead of separate contracts for each line of business. The network already serves more than 700 health plans, over 100,000 employers, and approximately 1.4 million contracted providers, giving Rocket Doctor a broad pathway to participate in the U.S. healthcare market.

Why the California Agreement Matters Now

California represents a critical entry point for telehealth growth because of its size, regulatory clarity on virtual care, and active workers' compensation market. By integrating state-compliant telehealth standards, Rocket Doctor gains a contracted path to reimbursement across multiple payer types, reducing reliance on any single insurance channel.

Company Advantage Through Diversified Access

Unlike traditional payer agreements limited to one type of coverage, this network relationship allows Rocket Doctor to participate in primary care, complementary services, workers' compensation, auto medical, and Medicare Advantage. The structure supports a more stable revenue base as the company scales its physician network in the state.

Key Assets and Near-Term Catalysts

Rocket Doctor AI is expanding its U.S. payer and physician footprint with Florida and Texas identified as additional target markets. Physician capacity is growing, with 22 clinically active U.S. physicians already onboarded and 33 more in credentialing. Completed U.S. patient visits rose from 86 in December 2025 to 1,144 in April 2026, while clinical hours increased from 75 to 624 over the same period. Each new payer relationship can potentially unlock access to one to two million or more covered lives.

The company is also advancing AI-enabled tools for patient intake, documentation, and follow-up that are designed to support physicians rather than replace them. These tools form part of the broader platform strategy and could drive further efficiency as volumes increase.

Broader Telehealth Sector Timing

The global telehealth market stood at US$186.41 billion in 2025 and is projected to reach US$1,272.81 billion by 2034 at a CAGR of 24.60%. North America accounted for roughly 45 percent of revenue in 2025. Reimbursement modernization, including new CMS billing codes, is making digital platforms more central to care delivery. Workers' compensation is emerging as a distinct growth channel, with the broader U.S. workers' compensation personal injury and PPO market expected to expand at a 5.4% CAGR from 2026 to 2033. Extended Medicare telehealth flexibilities through December 2027 provide additional regulatory runway.

Analyst Views and Valuation Context

¹Technical analyst Stewart Thomson issued a Strong Speculative Buy rating with price targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term. Fundamental Research Corp. reiterated a Buy rating and CA$1.55 target, citing intact growth trends supported by U.S. expansion and rising patient volumes.

Share Structure and Liquidity²

Rocket Doctor AI Inc. has a market cap of CA$60.62 million and 101.04 million shares outstanding. The 52-week range is CA$0.50 to CA$0.98. Management and insiders hold 4.24 percent of shares, with the remaining 95.76 percent held by retail investors. [OWNERSHIP_CHART-10594]

Key Investor Takeaways

The California network agreement provides diversified access to 60 million consumers across multiple reimbursement channels starting July 2026.
Patient visit volumes in the U.S. grew sharply from 86 in December 2025 to 1,144 in April 2026, supported by expanding physician capacity.
Expansion plans include Florida and Texas alongside continued California growth and additional payer relationships.
AI tools for intake, documentation, and follow-up are positioned to improve provider efficiency without replacing physicians.
Analysts maintain Buy or Strong Speculative Buy ratings with price targets ranging from CA$0.80 to CA$1.60.

Common Questions from Investors

Q: What does the new network agreement cover?
A: It covers primary care, complementary services, workers' compensation, auto medical, and Medicare Advantage through one national partner serving more than 700 health plans and approximately 60 million consumers.

Q: How fast is the telehealth market growing?
A: The market is projected to expand from US$186.41 billion in 2025 to US$1,272.81 billion by 2034 at a 24.60 percent CAGR.

Q: What are Rocket Doctor AI's near-term catalysts?
A: Continued U.S. state expansion, rising reimbursed patient volumes, and deployment of AI-enabled clinical tools.

Q: What are recent analyst ratings?
A: Recent ratings include a Strong Speculative Buy with targets up to CA$1.60 and a reiterated Buy with a CA$1.55 target.

The agreement marks a concrete step in Rocket Doctor AI's U.S. strategy and provides measurable scale through an established national network. Investors should monitor patient volume trends and additional state expansions for further evidence of execution.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

Rocket Doctor AI Signs Strategic Network Agreement to Expand California Reimbursement Access

Thu, 20 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/20/2026

New multi-channel partnership opens contracted entry points into workers' compensation, auto medical, and Medicare networks, further extending Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) U.S. partnering strategy.

On August 18, 2026, Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) announced that its wholly owned subsidiary, Rocket Doctor Inc.(“Rocket Doctor”) has entered into a strategic provider network agreement with a leading national technology-enabled network solutions partner to expand access to physician-led care across multiple channels in California. This agreement provides Rocket Doctor with participation advantage by focusing on networks including primary, complementary, workers' compensation, auto medical, and Medicare, unlike traditional payer agreements focused on a single line of business.

Through this partnership, Rocket Doctor has created the opportunity to work with upstream insurers, employer health plans, and other health care organizations. This national network serves more than 700 health plans, over 100,000 employers, roughly 60 million consumers, and includes 1.4 million contracted providers. This agreement became effective on July 1, 2026, with an initial one-year term with automatic annual renewals. The company considers this opportunity to be a further expansion of its U.S. strategy.

Expanding its footprint in California is a key operational priority for Rocket Doctor. Integrating California-compliant telehealth standards into the agreement ensures full alignment for covered service reimbursement, providing a strong foundation to capture further market demand. It will also establish a new contracted entry point into the California workers' compensation market.

"This agreement is particularly exciting because of the breadth of access it creates through a single relationship," said Dr. William Cherniak, Co-Founder and CEO of Rocket Doctor Inc. "As we continue to scale in California, expanding beyond traditional health insurance into areas such as workers' compensation and auto medical creates new opportunities for physicians to reach patients who need timely care. It is another important step toward building a diversified and sustainable reimbursement infrastructure around physician-led virtual care."

As a company, Rocket Doctor AI is focused on creating and providing physician-built, AI-powered solutions designed to make high-quality healthcare accessible remotely.

Telehealth Market Expanding Rapidly

The global telehealth market was valued at US$186.41 billion in 2025 and is projected to grow to US$219.31 billion in 2026, reaching US$1,272.81 billion by 2034 at a CAGR of 24.60%. North America was the largest regional market for telehealth in 2025, accounting for roughly 45% of global revenue.

In its 2026 Telehealth Market Outlook report, healthcare recruitment firm Storm3 pointed to reimbursement modernization as a defining trend for the sector this year, noting that new CMS billing codes and proposed SaaS-based pricing models reflect a shift toward digital platforms becoming "central to reimbursable care". The report also flagged regulatory uncertainty as an ongoing pressure point, citing an approaching "policy cliff" that has prompted calls from the American Telemedicine Association for permanent federal telehealth policy.

Workers' compensation is emerging as a distinct growth channel in virtual care. According to Risk Placement Services' 2026 US Workers' Compensation Market Outlook, rising medical costs and litigation trends are reshaping the market, with California's claims environment cited as a particular driver of nationwide change. Separately, an industry analysis of workers' comp technology trends noted that Medicare telehealth flexibilities were extended through December 31, 2027, giving carriers and self-insured groups more runway to build out telehealth infrastructure with "greater regulatory confidence".

That extended runway comes as the broader U.S. workers' compensation personal injury and PPO market is expected to grow at a 5.4% CAGR from 2026 to 2033, due to telehealth and digital care coordination platforms as key levers for improving claims efficiency and medical cost containment.

Analysts See Momentum, Reiterate Bullish Ratings

¹On March 17, 2026, technical analyst Stewart Thomson said that Rocket Doctor AI is "gaining momentum" as a digital health platform that helps make healthcare more accessible, especially to those in rural communities. "Virtual care offers convenience, flexibility, and ongoing access to a healthcare team, making it an excellent alternative to traditional clinic visits. However, not all "virtual care" platforms and services are alike," Thomson argued, noting that Rocket Doctor AI was built by doctors, so ". . . doctors who use it get exactly what they need."

Thomson gave the company a "Strong Speculative Buy" rating, with a short-term technical price target of CA$0.80, a medium-term target of CA$1.00, and a long-term target of CA$1.60.

Most recently, Sid Rajeev of Fundamental Research Corp. reiterated a "Buy" rating and price target of CA$1.55 on June 11, 2026, stating: "While Q1 results were impacted by higher costs and lower-than-expected patient volumes, we believe underlying growth trends remain intact. Supported by U.S. expansion, rising patient volumes, and sufficient liquidity, we expect meaningful operational and financial improvement over the coming quarters."

Catalysts Include State Expansion, Rising Patient Volumes, and AI Tool

According to its August investor overview, Rocket Doctor AI's near-term catalysts center on expanding its U.S. payer and physician network. The company’s August investor presentation identifies Florida and Texas, among other states, as part of its expansion pipeline, while its strategy includes extending existing payer relationships. The company reported it had achieved its initial U.S. growth from 22 clinically active U.S. physicians, several of whom were only onboarded mid-quarter following credentialing completion, and 33 physicians in credentialing, with imminent additional physician capacity expected to support higher patient volumes.

Another potential catalyst is growth in reimbursed patient volume. Rocket Doctor reported U.S. completed patient visits increasing from 86 in December 2025 to 1,144 in April 2026, while U.S. clinical hours rose from 75 to 624 over the same period. The company says each new payer relationship can potentially provide access to 1 million to 2 million or more covered lives, creating a potential path to additional patient volume and revenue as payer relationships expand.

The company is also developing AI-enabled tools for patient intake, clinical visits, documentation, and follow-up, with AI agents and clinical intelligence positioned as part of its broader platform. Rocket Doctor says these tools are designed to support providers rather than replace them. Further development and deployment of these AI capabilities, alongside expansion of its virtual-care network, could provide additional catalysts as the company works to scale its U.S. operations.

Ownership & Share Information²

Rocket Doctor AI Inc. has a market cap of CA$60.62 million, with 101.04 million shares outstanding. The company's 52-week range is CA$0.50-CA$0.98. Management & Insiders own 4.24% of shares, while the remaining 95.76% of shares are Retail. [OWNERSHIP_CHART-10594]

Frequently Asked Questions

Q: What is telehealth?
A: Telehealth uses telecommunications technology to provide healthcare services remotely, including virtual doctor visits, consultations, follow-up care, and other clinical services.

Q: How does telehealth work?
A: Telehealth allows patients and healthcare providers to connect remotely through secure digital platforms. Depending on the service, patients may receive consultations, diagnoses, treatment recommendations, or follow-up care without visiting a clinic in person.

Q: What are the benefits of telehealth?
A: Telehealth can improve access to healthcare by allowing patients to connect with providers remotely. It may reduce travel requirements, improve convenience, and help expand access to care in rural or underserved areas.

Q: How does telehealth reimbursement work?
A: Telehealth reimbursement allows healthcare providers to receive payment from insurers, employers, or other healthcare organizations for eligible virtual services. Coverage and reimbursement requirements can vary by payer, state, and type of healthcare service.

Q: What is a telehealth provider network?
A: A telehealth provider network connects physicians and other healthcare providers with insurers, employers, health plans, and patients. These networks can help providers gain access to covered patients and establish reimbursement pathways for eligible virtual healthcare services.

Q: What is the future of telehealth?
A: Telehealth is increasingly being incorporated into healthcare delivery alongside traditional in-person care. Continued development of reimbursement models, virtual-care infrastructure, and AI-enabled healthcare tools could support further adoption of telehealth and digital health services.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

Cleantech Developer Advances Five Platforms With 26% Revenue Growth

Tue, 18 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/18/2026

BioLargo reports 26% revenue growth excluding exited line, 54% gross margins and subsidiary-led funding model across medical, water and energy businesses.

BioLargo Inc. (BLGO:OTCQX) develops sustainable technologies that address environmental and cleantech challenges across multiple sectors. Retail investors are watching the company because its recent financial results show measurable progress in revenue and margins while it limits dilution at the parent level.

The broader cleantech sector is expanding rapidly as governments and industries seek solutions for water contamination, wound management, and long-duration energy storage. BioLargo stands out in this environment because it operates five distinct platforms and has chosen to raise most new capital inside its subsidiaries rather than through parent-level share sales.

Why BioLargo's Funding Approach Matters to Investors

Management reported that 86 percent of first-half capital came from subsidiary-level raises. Clyra Medical secured US$3.395 million in debt, and BioLargo Energy Technologies raised US$487,000 in equity, compared with only US$647,000 from selling BioLargo common stock. The approach trades equity dilution at the parent for contingent credit exposure. This strategy reduces immediate share-count pressure while still funding commercialization efforts.

Key Investor Takeaways

Revenue grew 26 percent year-over-year through the first half when the exited Pooph line is excluded, showing underlying business momentum.
Second-quarter gross margin reached 54 percent after shedding lower-margin private-label sales and tightening cost controls.
Five platforms are advancing simultaneously, with medical devices and consumer odor-control products closest to potential commercial inflection points.
Subsidiary financing covered 86 percent of new capital, limiting dilution at the BioLargo parent level.
Analysts maintain Speculative Buy and Buy ratings, citing the hub-and-spoke model and strategic partnerships across growing markets.

Unique Business Model Spreads Risk Across Platforms

BioLargo uses a hub-and-spoke structure in which it invents or acquires technology, proves it through prototyping, then partners with third parties for commercialization. The company currently runs five businesses: medical device products through Clyra, water treatment, industrial and consumer odor control, energy storage, and engineering services. The complete filing is available on its website.

Medical and Consumer Platforms Nearing Commercial Milestones

Clyra Medical contributed US$154,000 of first-half revenue. Its ViaCLYR copper-iodine solution holds FDA 510(k) clearance as a wound-irrigation product for acute and chronic wounds. The first U.S. distributor order arrived in February 2026, and an 18-country distribution agreement was signed in May. A surgical-irrigation version called Bioclynse is slated for launch through a national partner. On the consumer side, BioLargo CPG LLC plans an October relaunch of CupriDyne-based household products under full brand ownership.

Water Treatment, Engineering, and Energy Storage Advance Through Alliances

BioLargo Engineering, Science & Technologies generated US$1.888 million in first-half revenue, including recurring U.S. Air Force work and a new US$1.2 million contract for mineral-waste remediation. The Aqueous Electrostatic Concentrator has operated more than 10,000 hours at a New Jersey site, removing PFAS to non-detect levels. BioLargo Energy Technologies continues development of its Cellinity long-duration liquid-sodium battery and is now in customer and financing discussions.

Industry Trends Support Multiple Addressable Markets

The global wound-care market is projected to grow from US$22.22 billion in 2025 to US$30.48 billion by 2030 at a 6.5 percent CAGR, according to MarketsandMarkets. Rising chronic-disease rates, an aging population, and demand for cost-effective outcomes are driving adoption. The U.S. pet odor-control market is also expanding. Grand View Research valued the market at approximately US$6.47 billion in 2023 and projects it will reach about US$8.87 billion by 2030, indicating continued growth as manufacturers adapt their production strategies to serve the expanding opportunity.

Analyst Perspectives Highlight Partnership Strategy

¹Technical Analyst John Newell of John Newell & Associates highlighted BioLargo's healthcare operations through its subsidiary, Clyra Medical Technologies, in a March 11 report for Streetwise Reports. Newell noted the copper-iodine technology platform is supported by roughly 40 patents and that ViaCLYR's FDA clearance opens established distribution channels. He assigned a Speculative Buy rating. Oak Ridge Financial Analyst Richard Ryan described the operating model as a hub-and-spoke format and maintained his Buy rating, emphasizing that subsidiary structures spread risk while retaining significant ownership in high-growth markets.[OWNERSHIP_CHART-6976]

Share Structure and Upcoming Events²

Insiders and management own about 13.73 percent of BioLargo. Institutions with 13F holdings own 0.04 percent, with the balance held by retail investors. Market capitalization stands at US$32.91 million with 328.73 million shares outstanding. The stock trades in a 52-week range of US$0.10 to US$0.23. The company will host a stockholder town hall on September 10, 2026, at 1 p.m. Pacific time to review results and provide updates on all five platforms.

Common Questions from Investors

How did second-quarter revenue and margins compare with the prior quarter? Revenue rose 12 percent sequentially to US$1.248 million while gross margin improved to 54 percent from 51 percent a year earlier, aided by exiting low-margin private-label sales.

What are the nearest commercialization catalysts? Management highlighted the October consumer-product relaunch, first orders from the Al-Hikma distribution agreement, Bioclynse launch, mineral-waste pilot authorization, and potential commercial agreements in water treatment or energy storage.

Does the subsidiary financing model eliminate all dilution risk? No. While 86 percent of first-half capital was raised inside subsidiaries, BioLargo has guaranteed US$3.97 million of Clyra promissory notes, creating contingent credit exposure.

Where can investors find the full financial statements? The complete 10-Q filing and additional details are posted on the company's website under the SEC filings section.

BioLargo continues to execute a multi-platform strategy that balances near-term commercial opportunities with longer-term technology development. Investors should monitor execution on the announced milestones and the company's ability to maintain subsidiary-level financing momentum.

Important Disclosures:

BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosure for the quote from the John Newell article published on March 11, 2026

For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: BLGO:OTCQX, )

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline

Wed, 19 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/19/2026

Sarepta Therapeutics reports Q2 2026 results with $328.7M product revenue and new CEO Michael Severino leading pipeline progress in rare diseases. Read the latest on SRPT financials and catalysts.

Investors focused on rare disease treatments are tracking developments at Sarepta Therapeutics as the company reports second-quarter results and installs new leadership. The biotech sector continues to attract attention for its potential in genetic medicines, where companies like Sarepta Therapeutics target conditions with limited options.

Market Opportunity in Rare Genetic Diseases

The Duchenne muscular dystrophy (DMD) market was worth US$16.38 billion in 2025 and is expected to grow to US$62.13 billion by 2030, with a massive expected CAGR of 30.5%. North America was the largest regional market for DMD therapeutics in 2025. In February 2026, IQVIA discussed the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030.

They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity." Biopharma funding fell 20% between 2024 and 2025, according to an IQVIA analysis reported in a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Why Sarepta Therapeutics Stands Out Now

After appointing a new CEO, Sarepta Therapeutics Inc. (SRPT:NASDAQ) announced its Q2 2026 financial results on August 5, 2026, with $US328.7 million in net product revenue and operating income on both a GAAP and non-GAAP basis. Sarepta Therapeutics focuses on genetic medicine for rare diseases and is headquartered in Massachusetts, USA. The company currently has four FDA-approved therapies for treating Duchenne muscular dystrophy (DMD) and several additional programs in its pipeline.

Key Investor Takeaways

Sarepta reported US$328.7 million in Q2 2026 product revenue, led by PMO and ELEVIDYS sales.
Sarepta posted US$13.3 million in GAAP operating income and $86.5 million in non-GAAP operating income.
New CEO Michael Severino joined Sarepta as the company advances its rare disease pipeline.
Phase 1/2 studies in DM1 and FSHD remain on track for data readouts in the second half of 2026.
Sarepta's Huntington's disease program has begun dosing in its Phase 1 INSIGHTT study.
Sarepta narrowed its 2026 revenue guidance to US$1.2 billion to US$1.3 billion and ended Q2 with approximately US$945 million in cash, cash equivalents, restricted cash, and investments.

Financial Performance and Business Model

Net product revenue consisted of US$230.6 million from Sarepta's phosphorodiamidate morpholino oligomer (PMO) therapies and US$98.1 million from ELEVIDYS, the company's gene therapy for Duchenne muscular dystrophy (DMD). Total revenue was US$401.3 million for the quarter, compared with US$611.1 million in Q2 of 2025. Sarepta attributed the decrease to lower ELEVIDYS sales after an updated label limiting treatment to the ambulatory patient population, as well as the absence of a US$63.5 million Roche milestone payment that was included in 2025's results. However, the company reported that the decline in revenue was partially offset by higher contract manufacturing revenue related to ELEVIDYS supply delivered to Roche and US$10 million in license revenue.

Sarepta reported GAAP operating income of US$13.3 million for Q2 2026, compared with US$115.6 million in Q2 2025. Non-GAAP operating income was US$86.5 million, compared with US$162.8 million a year earlier. Research and development expenses declined to US$91.3 million in Q2 2026 from US$204.4 million in Q2 2025. Sarepta attributed the decrease to lower manufacturing and clinical expenses following a reprioritization of its development programs, as well as lower personnel and stock-based compensation expenses following its 2025 restructuring. Sarepta also recorded a US$39 million litigation contingency charge related to the potential resolution of certain patent litigation. The company said the potential settlement remains subject to further negotiations and will release definitive information once the settlement is completed.

Leadership Transition and Pipeline Catalysts

On the management side, Sarepta appointed Michael Severino, MD, as CEO and a member of its board effective July 28, 2026. Severino previously held senior leadership positions at AbbVie Inc. (ABBV:NYSE), Amgen Inc. (AMGN:NASDAQ), and Merck & Co. Inc. (MRK:NYSE). Former CEO Doug Ingram retired and is expected to remain with the company in an advisory role through the end of 2026.

Severino said in the release: "As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead. Our second quarter results, including US$328.7 million in total net product revenue and both GAAP and non-GAAP operating profitability, reflect the strength and resilience of our business. With important data readouts expected in DM1 and FSHD, continued progress across our broader pipeline, and a talented team dedicated to transforming the lives of patients with rare diseases, we have significant opportunities ahead and remain committed to delivering sustainable long-term value. Our priorities are clear: execute our commercial strategy, advance our promising siRNA pipeline, and continue allocating capital with discipline. With a strong balance sheet, an innovative pipeline, and an experienced leadership team, I believe Sarepta is well-positioned to deliver on its long-term potential." In an operational update, Sarepta reported that readouts from the multiple-ascending-dose cohorts of its ongoing Phase 1/2 studies in DM1 and FSHD remain on track for the second half of 2026.

For ELEVIDYS, Sarepta said that the company expects full enrollment of ENDEAVOR Cohort 8 by the end of 2026, with 12-week data from the full cohort expected in the first quarter of 2027. Finally, the company has also begun dosing in INSIGHTT, its first-in-human Phase 1 study of SRP-1005, an investigational small-interfering RNA (siRNA) therapy for Huntington's disease. The U.S. Food and Drug Administration has accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion of their accelerated approvals to traditional approvals. The applications are supported by data from the ESSENCE confirmatory study and published real-world evidence, according to the company. Sarepta Therapeutics Inc. is a worldwide biotech company that focuses on genetic medicine for rare diseases and is headquartered in Massachusetts, USA.

Analyst Views and Valuation Context

According to TipRanks, analysts have given Sarepta the following ratings: On August 10, 2026, Gavin Clark-Gartner of Evercore gave the company a Hold rating and a price target of US$19. On August 7, 2026, Eliana Merle of Barclays gave the company a Hold rating and a price target of US$20. On August 6, 2026, Ritu Baral of TD Cowen gave the company a Hold rating and a target price of US$17, Gil Blum of Needham gave the company a Sell rating, with no target price, Mitchell Kapoor of H.C. Wainwright gave the company a Sell rating, with a US$5 target price, Biren Amin of Piper Sandler gave the company a Hold rating, with a US$20 target price, Tazeen Ahmad of Bank of America gave the company a Sell rating with a US$18 target price, Michael Ulz of Morgan Stanley gave the company a Hold rating, with a US$25 target price, Kostas Biliouris of Oppenheimer gave the company a Buy rating, with a US$35 target price, Yun Zhong of Wedbush gave the company a Buy rating, with a US$35 target price, and Yanan Zhu of Wells Fargo gave the company a Buy rating, with a US$38 target price.

Finally, on August 7, 2026, Ilya Zubkov of Freedom Broker reiterated a "Buy" rating for the company, as well as a US$25 price target, writing: "The PMO portfolio remains the most resilient part of Sarepta's commercial business, and the quarter came in meaningfully better than our expectations . . . The long-term investment case depends on restoring ELEVIDYS' commercial trajectory and successfully advancing the siRNA pipeline as competition within PMOs increases."

Upcoming Pipeline Milestones

According to Sarepta's investor presentation, readouts from the multiple ascending dose (MAD) cohorts of its Phase 1/2 studies remain on track for the second half of 2026 for both SRP-1001, in facioscapulohumeral muscular dystrophy (FSHD), and SRP-1003, in myotonic dystrophy type 1 (DM1).

Share Structure and Ownership Details¹

Sarepta Therapeutics Inc. has a market cap of US$1.91 billion, with 105.63 million shares outstanding. The company's 52-week range is US$14.68-US$25.32. Institutions own 54% of shares, while Management & Insiders own 5%. The remaining 41% of shares are Retail. [OWNERSHIP_CHART-5368]

Retail investors should weigh the narrowed revenue guidance and litigation matters against the company's cash position and pipeline timelines when evaluating Sarepta Therapeutics.

Common Questions from Investors

Q: What does non-GAAP operating income exclude?
A: Non-GAAP operating income typically excludes stock-based compensation, restructuring charges, and other one-time items to show underlying business performance.

Q: Why did total revenue decline year-over-year?
A: The drop reflects lower ELEVIDYS sales due to label changes and the absence of a prior Roche milestone payment.

Q: What is the significance of the siRNA programs?
A: siRNA therapies aim to silence specific genes and represent a new approach in Sarepta's pipeline beyond its PMO and gene therapy platforms.

Q: How might the new CEO influence strategy?
A: Michael Severino brings experience from larger biopharma firms and has outlined priorities around commercial execution, pipeline advancement, and capital discipline.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: SRPT:NASDAQ, )

DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances

Wed, 19 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/19/2026

Satellos Bioscience reports positive six-month DMD trial data and FDA Fast Track status. Learn about its cash position, upcoming pediatric results, and analyst price targets.

Investors focused on rare disease treatments are tracking Satellos Bioscience as it advances a novel approach to Duchenne Muscular Dystrophy (DMD). The clinical-stage company is developing an oral small-molecule candidate that aims to restore the body's natural muscle repair process rather than relying solely on gene replacement strategies.

The Expanding Opportunity in DMD Therapeutics

The Duchenne Muscular Dystrophy market stood at US$16.38 billion in 2025 and is projected to reach US$62.13 billion by 2030, reflecting an expected CAGR of 30.5%. North America currently accounts for the largest share of spending on muscular dystrophy therapies. Broader pharmaceutical trends support continued investment in innovative treatments, with IQVIA discussing the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030. Industry observers note that spending growth will be driven by developed-market adoption of novel therapies in areas including oncology, immunology, and rare diseases.

Key Investor Takeaways

Satellos reported six-month data from its TRAILHEAD study showing reduced muscle fat fraction and increased upper-limb effort in all four participants, indicating potential improvement in muscle composition.
SAT-3247 received FDA Fast Track Designation for DMD while enrollment continues in the BASECAMP Phase 2 pediatric trial, with data expected in Q4 2026.
The company held US$61.8 million in cash and short-term investments as of June 30, 2026, providing runway through 2027, according to management.
R&D spending rose to US$9.6 million in the quarter, reflecting costs for ongoing trials and manufacturing scale-up.
Three analysts recently reiterated Buy ratings with price targets ranging from CA$24.96 to CA$55.46.
Satellos plans to submit an IND application for facioscapulohumeral muscular dystrophy later in 2026.

Why Satellos Stands Out in Muscle Regeneration

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) reported Q2 2026 financial results on August 13, 2026, alongside an update on its lead candidate SAT-3247. The drug is designed to inhibit AAK1, a protein involved in regulating muscle stem-cell activity, with the goal of enabling more effective regeneration in patients who lack functional dystrophin.

Unlike many gene-therapy approaches that require specialized delivery systems, SAT-3247 is an orally administered small molecule. This format could simplify dosing and expand access if clinical data continue to support safety and efficacy.

Clinical Pipeline and Near-Term Catalysts

The company is running two Phase 2 studies. BASECAMP is a global, randomized, placebo-controlled trial enrolling 51 ambulatory boys aged seven to nine with DMD. Primary endpoints focus on safety, tolerability, and dynamometry, while secondary measures include muscle quality and function. Data readout is targeted for Q4 2026.

TRAILHEAD is an open-label, 12-month study in adults that has already produced six-month follow-up results from four participants previously treated in a Phase 1b trial. Those data showed a continued favorable safety profile along with stable strength and improved quality-of-life measures. Enrollment is planned to expand to up to 30 participants across sites in the United States and Australia, with a further update expected in Q4 2026.

Satellos also remains on track to submit an Investigational New Drug application to the FDA for a second indication, facioscapulohumeral muscular dystrophy, later in 2026.

Financial Position and Operating Results

As of June 30, 2026, Satellos held US$61.8 million in cash, cash equivalents, and short-term investments, up from US$27.7 million at year-end 2025. The increase stemmed primarily from an equity offering completed in February 2026. Management states that current resources are expected to fund operations through 2027.

Research and development expenses reached US$9.6 million for the second quarter, compared with US$4.4 million a year earlier, driven by clinical trial costs and chemistry and manufacturing expenses. General and administrative expenses rose to US$2.5 million from US$1.9 million, reflecting higher headcount, reporting obligations, and Nasdaq listing costs. The company recorded a net loss of US$11.7 million, or US$0.56 per share, versus US$5.6 million, or US$0.39 per share, in the prior-year quarter.

Views and Valuation Context

Recent coverage includes reiterated Buy ratings from H.C. Wainwright (CA$24.96 target), Oppenheimer (CA$55.46 target), and Guggenheim (CA$31.89 target). Commentator Chen Lin noted the potential for significant upside if upcoming pediatric data prove strong, while cautioning that enrollment timing could shift the readout by a week or two.

Market observers also point to broader biopharma funding trends. A March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. observed that 2025 funding remained the third-highest of the past decade despite a year-over-year decline. A separate BCG talked about trends biopharma companies need to be aware of in 2026, emphasizing the need to reduce therapy complexity and align trial designs with real-world requirements.

Share Structure and Upcoming Events¹

Satellos Bioscience Inc. has a market capitalization of CA$278.82 million based on 20.84 million shares outstanding. The 52-week trading range spans CA$6.84 to CA$18.98. Institutions hold 50.60 percent of shares, management and insiders own 6.57 percent, and retail investors account for the remaining 42.83 percent.[OWNERSHIP_CHART-11545]

Common Questions from Investors

Q: How does SAT-3247 differ from existing DMD therapies?
A: SAT-3247 is an oral small-molecule drug that targets AAK1 to promote muscle stem-cell activity and natural regeneration, whereas many approved treatments focus on exon skipping or micro-dystrophin gene delivery.

Q: What does FDA Fast Track Designation mean for development timelines?
A: The designation provides more frequent FDA interactions and the possibility of rolling review, which can shorten the time between positive Phase 3 data and a potential marketing application if later trials succeed.

Q: When will investors see data from the pediatric BASECAMP study?
A: Management expects topline results in the fourth quarter of 2026, subject to final patient enrollment timing in the third quarter.

Q: What is the planned second indication for SAT-3247?
A: The company intends to file an IND for facioscapulohumeral muscular dystrophy later in 2026, expanding the potential addressable patient population beyond DMD.

Satellos continues to advance its clinical programs while maintaining a cash runway that supports operations through 2027. Retail investors should monitor enrollment updates and the Q4 2026 data releases for further clarity on the candidate's profile.

[SMNLINSERT]

Important Disclosures:

Cori FIsher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MSCL:TSX;MSLE:NASDAQ, )

Cleantech Firm Raises 86% of Capital Without Selling Stock

Tue, 18 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/18/2026

Cleantech innovator BioLargo Inc. (BLGO:OTCQX) files its financial results for the three and six months ended June 30. Find out how the company funded its five businesses while raising 86% of its capital without selling BioLargo stock.

BioLargo Inc. (BLGO:OTCQX), which develops and commercializes sustainable technologies for environmental and cleantech challenges, has filed its financial results for the three and six months ended June 30, according to an August 17 release.

The company will hold a stockholder town hall on Thursday, September 10, at 1 p.m. PT; the complete filing is available on its website.

"Setting aside the Pooph-related product line we exited last August, revenue grew approximately 26% year over year through six months, and 12% sequentially from the first to second quarter," BioLargo President and Chief Executive Officer Dennis P. Calvert said. "Second quarter gross margin reached 54%. We ended the quarter with US$2.2 million in cash. We had two ways to fund the businesses this year, sell BioLargo common stock, or raise capital inside the businesses doing the work and stand behind it. We chose the second and as a result 86% of the capital we raised in the first half was raised inside our subsidiaries rather than by selling BioLargo stock."

Calvert continued, "This helped us to advance five distinct businesses: medical device products, water treatment, industrial and consumer odor control, energy storage, and engineering services. Two opportunities are closest to commercial inflection: launching Clyra's flagship products across the United States and relaunching our consumer products. The other three, our water treatment, energy storage, and engineering businesses, are advancing toward scale through strategic alliances and dedicated capital. Our September 10 town hall will detail each of the five businesses, including the progress made and the milestones ahead."

Second-quarter revenue was US$1.248 million, up 12% from US$1.115 million in the first quarter but down 55% from US$2.777 million a year earlier, a drop driven mainly by exiting the private-label "Pooph" pet odor-control line in August 2025. Excluding Pooph, first-half revenue rose 26%, to US$2.363 million from about US$1.874 million a year earlier.

Clyra Medical contributed US$154,000 of first-half revenue, and consolidated service revenue rose 10%. Second-quarter gross margin improved to 54% from 51% a year earlier, helped by shedding low-margin private-label sales and stronger cost control at ONM Environmental, where cost of goods sold fell to 37% of revenue from 45%. First-half gross margin held at 48%, roughly flat year over year.

The second-quarter net loss widened to US$4 million from US$1.882 million a year earlier. Clyra Medical accounted for US$2.375 million, or 59%, of the consolidated quarterly loss, and about 48% of combined SG&A and R&D expense in the first half. Because BioLargo holds a 48% interest in Clyra, a meaningful portion of that loss is attributable to Clyra's minority investors rather than to BioLargo stockholders.

About 86% of first-half capital came through the subsidiaries rather than BioLargo share sales: Clyra raised US$3.395 million in debt and BioLargo Energy Technologies US$487,000 in equity, versus US$647,000 from selling BioLargo stock. Tied to these and notes issued in 2025, BioLargo had guaranteed US$3.97 million of Clyra promissory notes as of June 30. The approach trades equity dilution at the parent for contingent credit exposure.

At June 30, total assets were US$6.669 million (including US$3.499 million of current assets and US$2.188 million of cash), against US$4.765 million in current liabilities — a working capital deficit of US$1.266 million.

Management said it will keep pursuing subsidiary-level financing where practical, and pointed stockholders to the full liquidity discussion in the company's 10-Q.

Clyra and ViaCLYR™ Leading the Way

BioLargo is advancing several business platforms toward commercialization, led by Clyra Medical Technologies. Clyra's ViaCLYR™ copper-iodine solution is FDA-cleared under Section 510(k) specifically as a wound-irrigation solution for acute and chronic wounds — not for surgical or other applications, which the company is pursuing separately. ViaCLYR landed its first U.S. distributor order in February 2026 and an 18-country distribution deal with Dubai's Al-Hikma FZCO in May, and it booked US$154,000 in first-half revenue. Its next product, the surgical-irrigation solution Bioclynse, is slated to launch through a national distribution counterparty — extending the technology toward surgical use.

On the consumer side, the newly formed BioLargo CPG LLC plans an October relaunch of CupriDyne®-based household products, this time with BioLargo owning the brand and controlling the chain end to end, after the Pooph, Inc. license was revoked in September 2025. Its ONM Environmental unit keeps selling CupriDyne Clean and the equipment used to deploy it to municipalities, landfills and industrial customers, supported by recurring Southern California contracts.

BioLargo Engineering, Science & Technologies (BLEST) generated US$1.888 million in first-half revenue — including roughly US$100,000 a month from U.S. Air Force air-quality work — and won a US$1.2 million contract in April to design a mineral-waste remediation pilot in the western U.S. In water treatment, BioLargo's Aqueous Electrostatic Concentrator has run at Lake Stockholm, New Jersey, for more than six months (10,000-plus hours), removing PFAS to non-detect levels under EPA and state testing. And BioLargo Energy Technologies is developing Cellinity, a long-duration liquid-sodium battery built on abundant domestic materials with a projected 20-plus-year life — now in customer and financing talks, but with no signed contracts or revenue yet.

"We have important milestones that we expect to accomplish over the next six to nine months," Calvert said, pointing to the fall consumer-products launch, Al-Hikma's first orders, Bioclynse's rollout, authorization to build the minerals-processing commercial pilot, and a commercial agreement for its water-treatment or battery technology. "If those things happen, the thesis is working. If any of them do not, we will say so plainly and tell you why."

BioLargo will hold its stockholder town hall on September 10, 2026, at 1 p.m. Pacific (4 p.m. Eastern), where management plans to review second-quarter results and commercialization across its medical, water-treatment, odor-control, energy-storage and engineering businesses.

Expert: Portfolio Spans Several Cleantech Categories

¹Technical Analyst John Newell of John Newell & Associates highlighted BioLargo's healthcare operations through its subsidiary, Clyra Medical Technologies, in a March 11 report for Streetwise Reports. Newell said BioLargo has taken a deliberate path toward commercialization by first subjecting its proprietary technologies to extensive scientific validation and then working with established partners to expand their market reach. He noted that the company's portfolio spans water treatment, environmental remediation, air-quality solutions, energy storage and medical applications.

Newell identified Clyra as one of BioLargo's key healthcare assets, citing its copper-iodine technology, which has an antimicrobial component that functions as a preservative in the solution without causing cytotoxic effects. Newell also highlighted ViaCLYR's FDA 510(k) clearance, which allows the product to enter established medical-device distribution channels, while noting that the underlying platform is backed by approximately 40 issued and pending patents covering liquid, powder, hydrogel and antimicrobial dressing products.

Based on the potential of BioLargo's different technology platforms, Newell gave the company a Speculative Buy rating. He said the company's cautious commercialization model and emphasis on strategic partnerships could allow it to benefit from growing demand for advanced medical technologies and sustainable energy-storage solutions.

Oak Ridge Financial Analyst Richard Ryan described BioLargo's operating model in a May 18 report as a "hub and spoke format invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan maintained his Buy rating, arguing that BioLargo's use of independent operating subsidiaries to commercialize its technologies spreads risk while allowing the company to retain significant ownership positions in businesses pursuing opportunities across several rapidly expanding markets.

Catalysts: Addressing Growing Markets

The worldwide wound care market is projected to grow from US$22.22 billion in 2025 to US$30.48 billion by 2030, reflecting a 6.5% CAGR, according to MarketsandMarkets. The research firm attributed the anticipated expansion to increasing chronic disease rates, more traumatic injuries and burns, and the growing healthcare requirements of an aging population. As healthcare systems, insurers and manufacturers seek better patient outcomes while containing long-term expenses, wound management is becoming a greater priority across hospitals, outpatient clinics, home-care providers and long-term care settings.

MarketsandMarkets also expects demand for wound care products to rise as healthcare providers encounter more chronic wounds, diabetic foot ulcers, pressure injuries, venous leg ulcers, surgical wounds and trauma-related wounds. The report noted that wounds that heal slowly can increase hospitalization expenses, consume additional healthcare resources and contribute to more frequent readmissions, making effective wound treatment both a medical priority and an important consideration for healthcare organizations seeking to control costs and improve operational efficiency.

The U.S. market for pet odor-control and cleanup products is expanding as rising pet ownership and increased consumer spending on animal care encourage greater demand for products that help maintain household cleanliness. Grand View Research valued the market at approximately US$6.47 billion in 2023 and projects it will reach about US$8.87 billion by 2030, indicating continued growth as manufacturers adapt their production strategies to serve the expanding opportunity.[OWNERSHIP_CHART-6976]

"The increasing pet ownership and rising spending on pet care drive the market growth," Grand View said. "As more households in the U.S. welcome pets, the demand for products that maintain home hygiene and address pet-related odors has surged. Pet owners are more willing than ever to invest in high-quality solutions to manage pet waste and minimize unpleasant smells in their homes, fostering a strong demand for specialized odor control and clean-up products."

Grand View Research reported that 66% of U.S. households, representing 86.9 million homes, owned a pet in 2024, compared with 56% in 1988. The report also found that 97% of pet owners regarded their animals as family members, while 51% considered them equivalent to human family members, trends that are supporting continued demand for specialized odor-control and cleanup products.

"There has been a notable shift toward prioritizing home hygiene and cleanliness, especially in the wake of the COVID-19 pandemic," the report said. "Consumers are more aware of maintaining cleaner living environments, particularly in homes with pets. The concern over potential health issues from lingering pet odors and messes has prompted an increasing number of pet owners to adopt regular cleaning practices."

Ownership and Share Structure²

About 13.73% of BioLargo is owned by insiders and management. About 0.04% is held by institutions with 13F-disclosed institutional holdings only. The rest is retail.

Its market cap is US$32.91 million, with about 328.73 million shares outstanding. It trades in a 52-week range of US$0.10 and US$0.23.

Common Investor Questions

What did BioLargo report? On August 17, 2026, BioLargo filed its financial results for the three and six months ended June 30. Second-quarter revenue was US$1.248 million — up 12% sequentially from US$1.115 million, but down 55% from US$2.777 million a year earlier — and second-quarter gross margin expanded to 54% from 51%. The company will hold a stockholder town hall on September 10.

What's the "86% without selling stock" story? CEO Dennis P. Calvert said the company chose to fund its businesses mostly from within rather than by diluting shareholders: about 86% of first-half capital was raised inside the subsidiaries rather than through BioLargo share sales. Clyra Medical raised US$3.395 million in debt and BioLargo Energy Technologies US$487,000 in equity, versus just US$647,000 from selling BioLargo stock.

What are BioLargo's five businesses? Medical device products (Clyra Medical), water treatment, industrial and consumer odor control, energy storage, and engineering services. Calvert said the two closest to commercial inflection are launching Clyra's flagship products across the U.S. and relaunching consumer products, while water treatment, energy storage, and engineering advance toward scale through partnerships and dedicated capital.

When is the town hall, and what will it cover? BioLargo will hold its stockholder town hall on September 10, 2026, at 1 p.m. Pacific (4 p.m. Eastern), where management plans to review second-quarter results and detail commercialization progress and milestones across its medical, water-treatment, odor-control, energy-storage, and engineering businesses.

Important Disclosures:

BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosure for the quote from the John Newell article published on March 11, 2026

For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: BLGO:OTCQX, )

Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M

Mon, 17 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/17/2026

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has reported six-month TRAILHEAD data showing reduced muscle fat fraction and increased effort among the four adult DMD participants included in the interim analysis.

Financial results and an ongoing trial have life science investors watching a biopharma company's latest news.

Key Takeaways

Satellos Bioscience reported six-month TRAILHEAD data showing reduced muscle fat fraction and increased upper-limb effort among all four participants, with the company saying the findings suggest improved muscle composition.
SAT-3247 received FDA Fast Track Designation for DMD, while enrollment continues in the BASECAMP Phase 2 pediatric study, with data expected in Q4 2026.
The company held US$61.8 million in cash and short-term investments as of June 30, 2026, up from US$27.7 million at year-end 2025.
R&D expenses rose to US$9.6 million for the quarter (from US$4.4 million a year earlier), driven by TRAILHEAD/BASECAMP trial costs and manufacturing expenses.
Net loss widened to US$11.7 million for Q2 2026, compared to US$5.6 million in Q2 2025.
Satellos remains on track to submit an IND application to the FDA for a second indication, facioscapulohumeral muscular dystrophy (FSHD), later in 2026.

Satellos Targets Degenerative Muscle Diseases

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) reported Q2 2026 financial results on August 13, 2026, as well as an update on the clinical development program for SAT-3247, its lead drug candidate for Duchenne Muscular Dystrophy (DMD).

The press release included the following highlights:

Continued favorable safety and tolerability profile, stable strength, and improved quality of life reported in six-month follow-up data in TRAILHEAD Phase 2 adult DMD study
The company remains on track to report clinical data from its Phase 2 BASECAMP pediatric DMD study in Q4 2026
A strong financial position with US$61.8 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which the company expects to provide runway through 2027
SAT-3247 was granted FDA Fast Track Designation for DMD

SAT-3247 is an orally administered small-molecule drug candidate designed to restore muscle regeneration in people with DMD by targeting AAK1, a protein crucial to the body's natural muscle repair process. Satellos is currently advancing the drug candidate through two ongoing Phase 2 studies: BASECAMP, a global, randomized, placebo-controlled trial enrolling 51 ambulatory boys with DMD aged seven to nine, and TRAILHEAD, a 12-month, open-label study in adults with DMD.

BASECAMP is actively enrolling patients, with primary endpoints focused on safety, tolerability, and dynamometry, and secondary endpoints assessing muscle quality, function, and regeneration. Data from the trial is expected to be released in Q4 2026.

TRAILHEAD builds on six-month follow-up data that was announced in July, covering four adult participants who had previously completed the Phase 1b study. Satellos plans to expand enrollment to up to 30 participants, split between the U.S. and Australia, with a further update expected in Q4 2026.

On the financial side, Satellos provided the following Q2 2026 results:

The company had cash, cash equivalents, and short-term investments of US$61.8 million as of June 30, 2026, compared with US$27.7 million on December 31, 2025. The increase primarily reflects proceeds from an equity offering completed in February 2026, partially offset by cash used to fund ongoing operations.
Research & Development expenses increased to US$9.6 million for the quarter ended June 30, 2026, compared to US$4.4 million for the quarter ended June 30, 2025, primarily due to increased costs associated with the TRAILHEAD and BASECAMP studies, as well as chemistry and manufacturing control costs related to drug production to support the ongoing clinical trials.
General and Administrative expenses increased to US$2.5 million for the quarter ended June 30, 2026, as compared to US$1.9 million for the quarter ended June 30, 2025, primarily due to increased headcount, professional fees associated with public company reporting obligations, and costs associated with the Nasdaq listing.
For the quarter ended June 30, 2026, the company reported a net loss of US$11.7 million (US$0.56 loss per share), compared to a net loss of US$5.6 million (US$0.39 loss per share) for the quarter ended June 30, 2025.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.

DMD Market Seen Growing at 30.5% CAGR

The Duchenne Muscular Dystrophy (DMD) market was worth US$16.38 billion in 2025 and is expected to grow to US$62.13 billion by 2030, with a massive expected CAGR of 30.5%. North America is currently the largest market in need of muscular dystrophy treatments.

In February 2026, IQVIA discussed the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

Chen Lin Sees 10x Potential

On August 15, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? discussed the company's news, writing: "MSLE just reported; it looks like the results could be delayed by a week or two. They are confident the enrollment will finish in Q3, with a 12-week trial plus 2-3 weeks analyzing the results. It will be down to the wire at the end of the year. It all depends on when the last patient gets in, which should be sometime in September. I plan to have a meeting with the management in mid-September; hopefully, the trial is fully enrolled by then, and we can discuss exactly when we can expect the results. I see it has a good chance for 10x if the data is really good."

Recent analyst ratings include:

On August 17, 2026, Arthur He of H.C. Wainwright reiterated a "Buy" rating and a price target of CA$24.96.
On August 14, 2026, Kostas Biliouris of Oppenheimer reiterated a "Buy" rating and a price target of CA$55.46.
On July 9, 2026, Debjit Chattopadhyay of Guggenheim reiterated a "Buy" rating and a price target of CA$31.89.

FSHD IND Filing Coming Soon

Satellos is currently advancing SAT-3247 through its ongoing Phase 2 BASECAMP and TRAILHEAD studies in children and adults living with Duchenne, according to its investor presentation.

The press release stated that the company is on track to submit an Investigational New Drug application (IND) for FSHD to the FDA in the near future.

Ownership & Share Information¹

Satellos Bioscience Inc. has a market cap of CA$278.82 million, with 20.84 million shares outstanding. The company's 52-week range is CA$6.84-CA$18.98. Institutions own 50.60% of shares, while Management & Insiders own 6.57%. The remaining 42.83% of shares are Retail. [OWNERSHIP_CHART-11545]

Frequently Asked Questions

Q: What is Duchenne Muscular Dystrophy (DMD)?
A: Duchenne Muscular Dystrophy is a genetic disorder that causes progressive muscle weakness and loss of muscle function. It primarily affects boys and is associated with changes in the gene responsible for producing dystrophin, a protein that helps protect muscle fibers.

Q: What is facioscapulohumeral muscular dystrophy (FSHD)?
A: Facioscapulohumeral muscular dystrophy is a genetic muscle disorder that typically causes progressive weakness in the muscles of the face, shoulders and upper arms. Symptoms and severity can vary widely between individuals, and the condition can affect mobility and other muscle groups as it progresses.

Q: What are Phase 2 clinical trials?
A: Phase 2 clinical trials evaluate an experimental treatment in people with a particular disease or condition to gather evidence about its safety and effectiveness. These studies often involve more participants than earlier Phase 1 trials and are used to help determine appropriate dosing and identify potential treatment effects.

Q: What is an Investigational New Drug (IND) application?
A: An Investigational New Drug application is a submission to the U.S. Food and Drug Administration that allows a drug developer to request authorization to conduct clinical trials of an investigational drug in the United States. The application generally includes information about the drug, manufacturing process and planned clinical studies.

Q: What is FDA Fast Track Designation?
A: FDA Fast Track Designation is a program intended to facilitate the development and review of drugs that address serious conditions and have the potential to fulfill an unmet medical need. Designation can provide opportunities for more frequent communication with the FDA and may allow certain applications to receive expedited review mechanisms when applicable.

Important Disclosures:

Cori FIsher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MSCL:TSX;MSLE:NASDAQ, )

Sarepta Posts US$328.7M Results

Mon, 17 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/17/2026

Sarepta Therapeutics Inc. (SRPT:NASDAQ) reported US$328.7 million in Q2 2026 product revenue, with data readouts expected in DMD and FSHD this year.

Life sciences investors are watching Sarepta after a major management change and the release of its second-quarter 2026 financial results.

Key Takeaways

Sarepta reported US$328.7 million in Q2 2026 product revenue, led by PMO and ELEVIDYS sales.
Sarepta posted US$13.3 million in GAAP operating income and $86.5 million in non-GAAP operating income.
New CEO Michael Severino joined Sarepta as the company advances its rare disease pipeline.
Phase 1/2 studies in DM1 and FSHD remain on track for data readouts in the second half of 2026.
Sarepta's Huntington's disease program has begun dosing in its Phase 1 INSIGHTT study.
Sarepta narrowed its 2026 revenue guidance to US$1.2 billion to US$1.3 billion and ended Q2 with approximately US$945 million in cash, cash equivalents, restricted cash and investments.

New CEO, Narrowed Revenue Guidance

Net product revenue consisted of US$230.6 million from Sarepta's phosphorodiamidate morpholino oligomer (PMO) therapies and US$98.1 million from ELEVIDYS, the company's gene therapy for Duchenne Muscular Dystrophy (DMD). Total revenue was US$401.3 million for the quarter, compared with US$611.1 million in Q2 of 2025. Sarepta attributed the decrease to lower ELEVIDYS sales after an updated label limiting treatment to the ambulatory patient population, as well as the absence of a US$63.5 million Roche milestone payment that was included in 2025's results.

However, the company reported that the decline in revenue was partially offset by higher contract manufacturing revenue related to ELEVIDYS supply delivered to Roche and US$10 million in license revenue.

Research and development expenses declined to US$91.3 million in Q2 2026 from US$204.4 million in Q2 2025. Sarepta attributed the decrease to lower manufacturing and clinical expenses following a reprioritization of its development programs, as well as lower personnel and stock-based compensation expenses following its 2025 restructuring.

Sarepta also recorded a US$39 million litigation contingency charge related to the potential resolution of certain patent litigation. The company said the potential settlement remains subject to further negotiations and will release definitive information once the settlement is completed.

In an operational update, Sarepta reported that readouts from the multiple-ascending-dose cohorts of its ongoing Phase 1/2 studies in DM1 and FSHD remain on track for the second half of 2026. For ELEVIDYS, Sarepta said that the company expects full enrollment of ENDEAVOR Cohort 8 by the end of 2026, with 12-week data from the full cohort expected in the first quarter of 2027.

Finally, the company has also begun dosing in INSIGHTT, its first-in-human Phase 1 study of SRP-1005, an investigational small-interfering RNA (siRNA) therapy for Huntington's disease.

The U.S. Food and Drug Administration has accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion of their accelerated approvals to traditional approvals. The applications are supported by data from the ESSENCE confirmatory study and published real-world evidence, according to the company.

Sarepta Therapeutics Inc. is a worldwide biotech company that focuses on genetic medicine for rare diseases and is headquartered in Massachusetts, USA. The company currently has four FDA-approved therapies for treating Duchenne muscular dystrophy (DMD) and several additional programs in its pipeline.

DMD Market Growing Fast

The Duchenne Muscular Dystrophy (DMD) market was worth US$16.38 billion in 2025 and is expected to grow to US$62.13 billion by 2030, with a massive expected CAGR of 30.5%. North America was the largest regional market for DMD therapeutics in 2025.

Biopharma funding fell 20% between 2024 and 2025, according to an IQVIA analysis reported in a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

Is the Stock a Hold?

According to TipRanks, analysts have given Sarepta the following ratings:

On August 10, 2026, Gavin Clark-Gartner of Evercore gave the company a Hold rating and a price target of US$19.

On August 7, 2026, Eliana Merle of Barclays gave the company a Hold rating and a price target of US$20.

On August 6, 2026, Ritu Baral of TD Cowen gave the company a Hold rating and a target price of US$17, Gil Blum of Needham gave the company a Sell rating, with no target price, Mitchell Kapoor of H.C. Wainwright gave the company a Sell rating, with a US$5 target price, Biren Amin of Piper Sandler gave the company a Hold rating, with a US$20 target price, Tazeen Ahmad of Bank of America gave the company a Sell rating with a US$18 target price, Michael Ulz of Morgan Stanley gave the company a Hold rating, with a US$25 target price, Kostas Biliouris of Oppenheimer gave the company a Buy rating, with a US$35 target price, Yun Zhong of Wedbush gave the company a Buy rating, with a US$35 target price, and Yanan Zhu of Wells Fargo gave the company a Buy rating, with a US$38 target price.

Finally, on August 7, 2026, Ilya Zubkov of Freedom Broker reiterated a "Buy" rating for the company, as well as a US$25 price target, writing: "The PMO portfolio remains the most resilient part of Sarepta’s commercial business, and the quarter came in meaningfully better than our expectations . . . The long-term investment case depends on restoring ELEVIDYS' commercial trajectory and successfully advancing the siRNA pipeline as competition within PMOs increases."

Huntington's Program Begins Phase 1 Dosing

Ownership & Share Information¹

Frequently Asked Questions

Q: What is gene therapy?
A: Gene therapy is a treatment approach that uses genetic material to modify or replace faulty genes or affect how cells produce proteins.

Q: What is Duchenne muscular dystrophy (DMD)?
A: Duchenne muscular dystrophy is a genetic disorder that causes progressive muscle weakness and is most commonly diagnosed in boys.

Q: What is an siRNA therapy?
A: Small interfering RNA (siRNA) therapy uses RNA molecules to reduce the production of specific proteins by targeting messenger RNA.

Q: What is a PDUFA date?
A: A PDUFA date is the FDA's target date for completing its review of a new drug application or supplemental application under the Prescription Drug User Fee Act.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: SRPT:NASDAQ, )

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

Fri, 14 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/14/2026

Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.

Doximity Inc. (DOCS:NYSE) delivers digital workflow and AI solutions that connect physicians with essential clinical tools. The company operates at the intersection of healthcare technology and professional networking, serving a market where agentic AI adoption is accelerating rapidly.

Healthcare AI Market Expands as Providers Adopt Workflow Tools

Global spending on agentic AI in healthcare is projected to climb sharply, with one forecast placing the 2025 market at US$1.45 billion and expecting growth to US$19.71 billion by 2034. Fortune Business Insights notes that North America already accounts for more than 45% of this segment. Similar momentum appears in digital health overall, where An August announcement for the Global Health Exhibition highlighted rising investment in AI-driven diagnostics and clinical operations. Broader generative AI applications in clinical trials are also forecast to expand, though SNS Insider published a forecast for the generative AI in clinical trials market that some observers view as overstated; at least one other forecaster using an effectively identical growth rate offers a materially smaller base figure.

Key Investor Takeaways

Doximity reached more than 85% of U.S. physicians and reported over 800,000 unique active workflow providers in its most recent fiscal quarter.
Workflow active prescriber growth exceeded 30% year over year while AI Search queries rose more than 25% quarter over quarter.
Fiscal first-quarter revenue grew 7% to US$156.6 million, though GAAP net income declined to US$24.3 million from the prior-year level.
Full-year fiscal 2027 revenue guidance was raised to a range of US$671 million to US$681 million.
Analyst price targets span US$18 to US$47, reflecting a wide range of views on growth sustainability and margin pressure.
Institutional investors hold nearly 92% of shares, providing a stable but concentrated ownership base.¹

Why Doximity Stands Out in Digital Health

The company combines a large physician network with subscription-based marketing solutions and an expanding suite of clinical AI products. Its platform reaches a broad audience across specialties, which supports both pharmaceutical and health-system marketing revenue. Doximity also operates staffing and telehealth modules that leverage the same user base.

Financial Results Show Revenue Growth With Margin Pressure

The company recently released fiscal 2027 first-quarter revenue of US$156.6 million for the three months ended June 30, up 7% from US$145.9 million in the same period a year earlier. GAAP net income fell to US$24.3 million from US$53.3 million, producing a net margin of 15.5%. Non-GAAP net income declined to US$55.0 million while adjusted EBITDA decreased 6% to US$74.8 million. Operating cash flow dropped 32% to US$42.0 million. The company ended the quarter with US$273.6 million in cash and US$414.2 million in marketable securities.

AI Suite and Engagement Metrics Provide Growth Catalysts

Doximity reported that its clinical AI assistant, Doximity Ask, ranked as the top-performing U.S.-based model on the NOHARM benchmark. The company also offers Scribe and Dialer within a free, HIPAA-compliant suite. Co-founder and CEO Jeff Tangney said in the company news release that workflow active prescriber growth exceeded 30% year over year. Doximity's Fall 2026 investor presentation outlines an AI Search offering and notes that AI users represent roughly half of workflow quarterly active users. The presentation further states that 53% of large U.S. pharmaceutical brands have signed marketing agreements with the company.

Analyst Views and Price Targets Reflect Divergent Outlooks

Several firms issued updates in mid-August. Needham maintained a Buy rating with a US$41 target while Piper Sandler raised its target to US$47. Wells Fargo downgraded the stock to Underweight with an US$18 target. Other targets range from US$24 to US$40, illustrating varied expectations around revenue acceleration and profitability.

Guidance and Commercial Reach Set Near-Term Milestones

For the second quarter ending September 30, Doximity guided revenue between US$170 million and US$171 million. Full-year fiscal 2027 revenue guidance now stands at US$671 million to US$681 million with adjusted EBITDA between US$309 million and US$329 million. The company continues to price marketing solutions based on audience size and module mix, reporting strong return-on-investment metrics for both health-system and pharmaceutical customers.

Ownership and Share Structure¹

Institutions hold 91.84% of Doximity while management and insiders own 2.81%. The company has 178.25 million shares outstanding and a market capitalization of approximately US$4.74 billion. Its 52-week trading range spans US$17.15 to US$76.51. [OWNERSHIP_CHART-10443]

Common Questions from Investors

What drove Doximity's fiscal first-quarter revenue growth? Subscription revenue from pharmaceutical and health-system marketing, supported by 107% net revenue retention overall and 112% among top customers, produced the 7% year-over-year increase.

How does Doximity measure AI usage growth? The company tracks AI Search query growth, which rose more than 25% quarter over quarter, and notes that AI users comprise about half of its workflow quarterly active users.

What is the size of Doximity's accessible market? The investor presentation identifies an US$18.5 billion total addressable market across existing segments plus billions more from the new AI Search offering.

How many physicians does the platform reach? Doximity reports access to more than 85% of U.S. physicians across specialties.

What is the current employee count and R&D focus? As of June 30, Doximity employed 885 people, with more than 40% working in research and development.

Retail investors should weigh revenue growth against declining GAAP margins and monitor execution on the new AI Search initiatives. The concentrated institutional ownership base may contribute to share-price volatility around quarterly updates.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: DOCS:NYSE, )

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

Fri, 14 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/14/2026

Doximity Inc. (DOCS:NYSE) reported 7% revenue growth as workflow active prescribers increased more than 30% year over year and AI Search queries climbed more than 25% quarter over quarter.

Doximity Inc. (DOCS:NYSE) reported fiscal 2027 first-quarter revenue of US$156.6 million for the three months ended June 30, up 7% from US$145.9 million in the same period a year earlier.

The company reported net income of US$24.3 million, compared with US$53.3 million a year earlier. Net income margin was 15.5%, compared with 36.5%. Diluted net income per share was US$0.13, compared with US$0.27.

Non-GAAP net income was US$55.0 million, compared with US$71.9 million, with a non-GAAP net income margin of 35.1%, compared with 49.2%. Non-GAAP diluted net income per share was US$0.29, compared with US$0.36.

Adjusted EBITDA totaled US$74.8 million, compared with US$79.8 million, a decrease of 6% year over year. Adjusted EBITDA margin was 47.7%, compared with 54.7%.

Operating cash flow was US$42.0 million, down 32% from US$62.1 million, while free cash flow was US$39.6 million, down 34% from US$60.1 million. Doximity ended the quarter with US$273.6 million in cash and cash equivalents, compared with US$219.2 million as of March 31.

The company also reported US$414.2 million in marketable securities as of June 30. Total assets were US$1.084 billion, while total liabilities were US$167.8 million.

Doximity said engagement included year-over-year workflow active prescriber growth of more than 30% and quarter-over-quarter AI Search query growth of more than 25%. The company's August investor presentation listed more than 800,000 unique active workflow providers for the fiscal quarter ended March 31 and said AI users represented approximately half of workflow quarterly active users. The presentation also reported that Doximity reaches more than 85% of U.S. physicians.

"We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement," co-founder and CEO Jeff Tangney said in the company news release. "In Q1, we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter."

The investor presentation stated that Doximity Ask outperformed OpenEvidence and leading frontier AI models in the NOHARM benchmark, which it described as one of the most comprehensive independent evaluations of clinical AI safety to date.

Doximity's first-quarter revenue metrics included 127 customers with trailing 12-month subscription revenue above US$500,000, an increase of 7% year over year. The company reported a net revenue retention rate of 107% for the total company and 112% among its top 20 customers.

AI Moves Deeper Into Healthcare Workflows as Digital Health Adoption Expands

Fortune Business Insights valued the global agentic AI in healthcare market at US$1.45 billion in 2025 and projects it will grow from US$1.83 billion in 2026 to US$19.71 billion by 2034, a compound annual growth rate of 34.61%. North America accounted for 45.52% of the market in 2025.

The firm describes a shift away from conversational AI toward systems that carry out multi-step tasks — extracting data, generating documentation, and assigning work — rather than simply responding to prompts. Applications identified in the report include clinical documentation and workflow automation, clinical decision support and diagnostics, patient access and operational efficiency, revenue cycle management, and virtual health assistants and monitoring. Natural language processing led the technology segment in 2025, and healthcare providers led among end users.

Estimates for this market vary widely by firm, with other researchers placing the 2025 base between roughly US$0.7 billion and US$1.5 billion and projecting materially different growth rates, so the figures above should be read as one house's methodology rather than a settled measure.

An August announcement for the Global Health Exhibition said digital health investment is increasingly focused on deploying AI across clinical workflows, diagnostics, hospital operations, and patient engagement. The release cited a projection that Saudi Arabia's digital health market will reach US$11.07 billion by 2033 — a Grand View Research estimate; other forecasters have published higher figures for the same market and year.

"Digital transformation is changing how healthcare is delivered," Dr. Fouziyah AlJarallah, CEO of Hayat National Hospital, said in the announcement, pointing to improved patient outcomes and better-connected services.

The announcement framed healthcare systems as moving from AI experimentation toward implementation at scale, highlighting AI-powered diagnostics, connected care, healthcare data management, and clinical decision support. Professor Shafi Ahmed, consultant surgeon at Barts Health NHS Trust and a speaker at the event's Digital Health Forum, has similarly argued that digital health improves access to care and supports clinicians in delivering better patient outcomes.

On August 13, SNS Insider published a forecast for the generative AI in clinical trials market, valuing it at US$245.82 billion in 2025 and projecting US$1,986.53 billion by 2035 at a 23.27% compound annual growth rate from 2026 through 2035. Those absolute figures appear to be misstated at the source: a market of US$245.82 billion would be several times larger than the entire global clinical trials industry, and at least one other forecaster using an effectively identical growth rate sizes the same market at US$2.45 billion in 2025, reaching US$19.86 billion by 2035 — a factor of 100 smaller. The growth rate and segment shares are consistent across both; the units are not.

SNS Insider attributes demand to the rising complexity and cost of clinical research, with pharmaceutical and biotechnology companies evaluating generative AI for protocol design, patient recruitment, documentation, data analysis, and trial monitoring. By its segmentation, cloud-based solutions represented approximately 63.40% of the market in 2025, and patient recruitment and matching approximately 34.80% by application, with North America accounting for roughly 31.29% of global revenue.

Third-Party Expert Analysis: Analysts Set Targets

Several firms issued updates on August 7. Needham analyst Ryan MacDonald reiterated a Buy rating with a US$41 price target. Evercore analyst Elizabeth Anderson set a US$40 price target and maintained an in-line rating. BMO Capital Markets analyst Sean Dodge reiterated a Market Perform rating with a US$30 price target, while Canaccord Genuity analyst Richard Close set a US$36 price target.

Also on August 7, Piper Sandler analyst Jessica Tassan reiterated an Overweight rating and increased the price target to US$47 from US$42. JPMorgan analyst Alexei Gogolev maintained a Neutral rating and raised the price target to US$31 from US$26.

Wells Fargo analyst Stan Berenshteyn downgraded Doximity from Equal Weight to Underweight on August 10 and set a US$18 price target. Weiss Ratings reiterated a Sell (D+) rating on August 12, with no individual analyst or price target listed by MarketBeat.

The most recent entries on MarketBeat were dated August 13. Truist analyst Jailendra Singh maintained a Hold rating and increased the firm's price target to US$24 from US$19.

AI Search, Commercial Reach, and Fiscal 2027 Guidance Set the Next Milestones

For its fiscal second quarter ending September 30, Doximity provided revenue guidance of US$170 million to US$171 million and adjusted EBITDA guidance of US$80.5 million to US$81.5 million.

For the fiscal year ending March 31, 2027, the company updated its guidance to revenue between US$671 million and US$681 million and adjusted EBITDA between US$309 million and US$329 million.

Doximity's Fall 2026 investor presentation identified AI Search as an additional offering alongside its existing pharmaceutical marketing, health system marketing, staffing, and telehealth businesses. The presentation listed a total accessible market of US$18.5 billion across pharmaceutical marketing, health system marketing and staffing, and telehealth, with AI Search adding what the company described as billions of dollars in 2026.

The company's clinical AI suite includes Scribe, Ask, and Dialer. Doximity described the suite as free, HIPAA-compliant, and private to each clinician. The presentation also highlighted Doximity's Pathway AI acquisition, describing the acquired team as half doctors with seven years of AI experience and identifying a medical semantic model designed for maximum accuracy.

Doximity also outlined an AI Search offering that includes Ask AI placement and what the company called "acceleration of ecosystem message." Its core commercial modules include long-form, video, and short-form Newsfeed formats as well as point-of-care and formulary offerings, with customized packages created for customers.

The presentation described a dynamic integrated offering using more than 300 data and insights inputs, including proprietary Doximity, IQVIA, brand and content signals, together with an AI orchestration engine.

Doximity identified marketing solutions as its largest revenue driver. Its subscription pricing model incorporates audience, including specialty, the number of audience members, and the type and number of modules. The presentation reported a 17-to-1 return on investment for health systems based on LexisNexis data and approximately 10-to-1 for pharmaceutical customers using IQVIA methodology. [OWNERSHIP_CHART-10443]

The presentation also showed Doximity had signed 53% of U.S. pharmaceutical brands with more than US$100 million in sales as of March 31, while 47% were not signed. Among U.S. brands with US$1 million to US$100 million in sales, 11% were signed, and 89% were not signed.

As of June 30, Doximity had 885 employees, with more than 40% in research and development.

Ownership and Share Structure¹

91.84% of Doximity is held by institutions, and 2.81% is owned by management and insiders. The rest is retail.

Doximity has a market cap of US$4,739.56 million, 178.25 million outstanding shares, and a 52-week range of US$17.15 to US$76.51.

Frequently Asked Questions

What were Doximity's fiscal Q1 2027 revenue and earnings?
Doximity Inc. (DOCS:NYSE) reported fiscal 2027 first-quarter revenue of US$156.6 million for the three months ended June 30, up 7% from US$145.9 million a year earlier. Net income was US$24.3 million, or US$0.13 per diluted share, while adjusted EBITDA was US$74.8 million.

What was Doximity's fiscal 2027 revenue guidance?
Doximity Inc. (DOCS:NYSE) provided fiscal second-quarter revenue guidance of US$170 million to US$171 million and adjusted EBITDA guidance of US$80.5 million to US$81.5 million. For the fiscal year ending March 31, 2027, the company updated its guidance to revenue of US$671 million to US$681 million and adjusted EBITDA of US$309 million to US$329 million.

What is Doximity Ask, and how is Doximity using AI in healthcare?
Doximity Ask is the company's HIPAA-compliant generative AI clinical research tool and writing assistant. Doximity Inc. (DOCS:NYSE) also offers Scribe and Dialer as part of its clinical AI suite, and the company reported AI Search query growth of more than 25% quarter over quarter.

How did Doximity Ask perform in the NOHARM clinical AI benchmark?
Doximity Inc. (DOCS:NYSE) said Ask was the top-performing U.S.-based model in the NOHARM benchmark. The company's investor presentation stated that Doximity Ask outperformed OpenEvidence and leading frontier AI models in the benchmark, which it described as an independent evaluation of clinical AI safety.

How many healthcare providers and physicians use Doximity?
Doximity Inc. (DOCS:NYSE) said its network included more than 85% of U.S. physicians across specialties and practice areas. Its investor presentation reported more than 800,000 unique active workflow providers for the fiscal quarter ended March 31.

How fast is Doximity's healthcare workflow and AI usage growing?
Doximity Inc. (DOCS:NYSE) reported workflow active prescriber growth of more than 30% year over year during the fiscal first quarter, while AI Search query growth exceeded 25% quarter over quarter.

What sector is Doximity Inc. (DOCS:NYSE) in?
Doximity operates in the digital health and healthcare technology sector. Its platform combines a professional network for medical professionals with digital workflow, communications, telehealth, scheduling, clinical reference and AI tools.

Important Disclosures:

James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: DOCS:NYSE, )

Virtual Care AI Provider Expands Potential Access to 100k+ New York Covered Lives

Thu, 13 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/13/2026

Rocket Doctor AI expanded potential in-network access to more than 100,000 additional eligible covered lives in New York through a new payer agreement, while continuing to expand its physician network and healthcare AI capabilities in the United States.

Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) recent payer agreement highlights growing demand for scalable virtual care solutions that integrate licensed physicians with digital platforms. The digital health sector continues to attract attention from retail investors seeking exposure to companies that combine technology with established reimbursement pathways.

The broader healthcare technology market faces pressure from aging populations and rising chronic disease rates, yet benefits from tools that extend access beyond traditional clinic walls. Rocket Doctor AI stands out because its platform already connects patients to in-network physicians across multiple states while building AI features designed specifically for clinical workflows.

Why Rocket Doctor AI Stands Out in Digital Health

Under the agreement, Rocket Doctor is now accessible to more than 100,000 additional eligible lives across participating individual Medicare Advantage PPO and commercial health plans in the New York metropolitan region and select upstate counties. The estimate excludes millions of members covered through administrative services only or self-insured plans. The payer also participates in a national reciprocal network program, allowing eligible out-of-state members to access Rocket Doctor's in-network physicians while traveling in New York.

With the latest agreement, Rocket Doctor reports potential in-network access to approximately 10 million covered lives in New York and approximately 24 million covered lives nationwide through its commercial and public payer relationships. These figures represent potential access to people covered by participating plans, not the company's current patient population. The agreement was signed on July 15 and has an initial one-year term, with automatic one-year renewals unless terminated or non-renewed by either party in accordance with its terms.

Key Investor Takeaways

“Rocket Doctor AI secured in-network access to more than 100,000 additional eligible New York covered lives through a new payer agreement signed July 15.
The company reports potential in-network access to roughly 10 million covered lives in New York and 24 million nationwide through its payer relationships.
Physician numbers continue to grow, with 22 clinically active US doctors and 33 more in credentialing as of the August investor overview.
US patient visits rose steadily from 86 in December 2025 to 1,144 in April, showing operational traction.
Technical analyst Stewart Thomson assigned a Strong Speculative Buy rating with price targets of CA$0.80 short term CA$1.00 medium term and CA$1.60 long term.¹
Expansion plans target Florida and Texas while extending current payer contracts across Medicaid, Medicare Advantage, and commercial channels.

Unique Business Model and AI Advantages

Rocket Doctor recently announced expanded in-network access to physician-led virtual care in New York through a new agreement entered into by doctors using its digital health platform and marketplace.

Rocket Doctor's programs allow patients to connect with licensed physicians from home for services including urgent care, chronic disease management, preventive health, pediatrics, and mental health support. Eligible members can access the services through their existing insurance coverage under Rocket Doctor's in-network participation.

"This agreement represents another important milestone in our strategy to expand reimbursed access to physician-led care," said Dr. William Cherniak, co-founder and chief executive officer of Rocket Doctor. "By increasing the number of patients who can connect with physicians through their existing health benefits, we are helping reduce financial barriers to care while building a more sustainable model for delivering high-quality virtual care at scale."

Industry Timing and Broader Digital Health Trends

The World Bank Group's Paschal Donohoe wrote on August 3 that healthcare systems globally had been facing pressure from aging populations, rising chronic disease, and growing demand for specialized care, while geography continued to affect access to timely care. He described digital technology as a way to extend healthcare services when it was "well-designed, governed responsibly, and embedded in broader health-system reform."

Donohoe pointed to virtual healthcare programs that had combined medical expertise with digital technologies to provide remote services, including virtual critical care, specialty consultations, and home-care services. He wrote that "digital technology can improve patient care" by extending expertise beyond hospital walls.

At the same time, Donohoe cautioned that technology was not a substitute for the broader healthcare system. "Virtual care is not a shortcut to deeper healthcare reforms," he wrote. "It cannot replace skilled providers, systems, or patient trust." He said digital healthcare raised legal and regulatory questions and that countries needed to determine which services were clinically effective and which training approaches best helped workers serve patients.

A report distributed through EIN Presswire on August 10 said U.S. healthcare and pharmaceutical marketers were expected to spend US$26.15 billion on digital advertising during 2026, representing a 5.6% year-over-year increase, according to eMarketer. The report also said 2025 marked the first year that social media spending exceeded linear television spending in the category.

In an August 11 article, Gilda D'Incerti examined healthcare AI adoption through the industry's previous experiences with electronic health records, revenue-cycle modernization, telehealth expansion, and other digital transformations. She wrote that healthcare's experience had shown that technological implementation depended on organizational factors, including workflow redesign, clinician acceptance, and training.

Analyst Views and Technical Outlook

¹Technical analyst Stewart Thomson gave Rocket Doctor AI Inc. a Strong Speculative Buy technical rating in a March 17 report, citing the company's healthcare technology, U.S. payer relationships, and physician-oriented platform.

Thomson described Rocket Doctor's technology as being developed around the needs of healthcare providers. He wrote that the company's AI platform "is designed by doctors, so doctors who use it get exactly what they need," and said its approach was "centered on enhancing provider capabilities, not replacing clinical decisions." He also cited smart triage and matching technology, remote patient monitoring, multilingual care, and support for multiple medical specialties.

The analyst also discussed Rocket Doctor's expansion in the United States. He cited an in-network agreement in New York that he said increased the company's nationwide reach to more than 15 million members. Thomson also referenced a US$1 million Healthy Aging Program grant launched with CVS Health Foundation, through a partnership the Company announced with Engagewell on July 10, 2025.

Thomson established three technical price targets for the shares: CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term.

Key Assets, Projects, and Ongoing Catalysts

Rocket Doctor AI's August investor overview identified additional state expansion, physician credentialing, and development of its healthcare AI products among the company's ongoing programs.

The presentation identified Florida and Texas among the company's state expansion pipeline and listed its strategy as extending existing relationships with payers. At the time reflected in the presentation, Rocket Doctor listed 9,875,993 covered lives with potential in-network access in New York, 8,126,637 in California, and 3,180,599 in Maryland.

The company's U.S. payer approach covers channels including: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits, commercial insurance, and out-of-network patients. The presentation stated that each payer relationship could provide indicative potential access to 1 million to 2 million or more covered lives.

Physician credentialing represents another ongoing work stream. The presentation reported 22 clinically active U.S. physicians and another 33 physicians in credentialing. It also listed pending physician capacity at three times the number of clinically active U.S. physicians.

Rocket Doctor AI also described a connected suite of healthcare AI solutions encompassing its digital health platform and marketplace, AI Assistants, Electronic Medical Records (EMR), access to Bluetooth-enabled medical devices, AI Scribe, the Global Library of Medicine (GLM), and billing and revenue reconciliation.

The company's AI-supported care workflow covers intake, patient visits, and follow-up. Intake features listed in the presentation include symptom-based smart intake, doctor and patient matching, auto-booking, initial care assessments, and an AI agent. Patient-visit functions include AI-driven diagnostic support, questioning through chat and video, appointments, referrals, labs and imaging, and real-time updates to the patient chart. Follow-up functions include chronic-condition management, future appointments and reminders, preset follow-ups, and an AI agent.

Rocket Doctor AI's Global Library of Medicine (GLM) has been in development since 2016, with more than 25,000 hours of input from hundreds of clinicians globally and approximately 10,000 or more expert medical reviews. The GLM includes more than 1,000 diseases and 17,000 symptoms in real time and suggests appropriate lab tests and imaging, treatment options, and billing codes. The company also described plug-and-play API integration for connecting the system to other platforms, such as EMRs, AI Scribes, and/or other healthcare systems offering patient-facing services.

The presentation also identifies continued physician and patient activity and growth in the United States. Total completed U.S. patient visits increased from 86 in December 2025 to 177 in January, 464 in February, 678 in March, and 1,144 in April. U.S. clinical hours increased from 75 in December to 110 in January, 434 in February, 577 in March, and 624 in April. [OWNERSHIP_CHART-10594]

Share Structure and Market Position

As of August 13, 2026, Insider ownership of Rocket Doctor AI totals 4.24%. Retail investors hold the rest.²

As of August 13, 2026, Rocket Doctor AI has approximately 101.03 million shares outstanding. Its market capitalization is approximately CA$59.61 million, and its 52-week trading range is CA$0.47 to CA$0.98 per share.

Common Questions from Investors

How many additional covered lives did the latest New York agreement add?

The agreement provides in-network access for more than 100,000 additional eligible lives across Medicare Advantage PPO and commercial plans in the New York region and select upstate counties.

What is Rocket Doctor AI's current potential reach across New York and the United States?

Following the agreement, the company reports potential in-network access to approximately 10 million covered lives in New York and 24 million nationwide.

Which states are targeted for further expansion?

The August investor overview lists Florida and Texas in the state expansion pipeline while focusing on extending existing payer relationships.

What growth has been reported in US patient visits?

Completed US patient visits rose from 86 in December 2025 to 1144 in April, according to the investor overview.

What price targets did analyst Stewart Thomson set?

Thomson set technical targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term.

Retail investors evaluating Rocket Doctor AI should consider both the expanding payer footprint and the need for continued physician credentialing and revenue growth to support long-term sustainability.

Important Disclosures:

Rocket Doctor is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom

Thu, 13 Aug 2026 00:00:00 PST

The company's flagship gene therapy posted a fifth consecutive sequential decline in 2Q26, with DM1 and FSHD data updates seen as the next potential value inflection points.

On August 6, 2026, analysts Mitchell S. Kapoor, MBA, MS, and Raghuram Selvaraju, Ph.D., MBA, MS, of H.C. Wainwright & Co. reiterated a Sell rating and a US$5.00 per share price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), implying roughly 69% downside from the August 5, 2026, closing price of US$15.93, following second-quarter results that showed continued erosion across the company's marketed Duchenne muscular dystrophy (DMD) franchise alongside a share-price reaction the analysts characterized as dismissive of that decline.

Muted Market Reaction Implies Value Assigned to Early-Stage Programs

ELEVIDYS generated US$98.1 million in 2Q26, 2.3% below the US$100.4 million consensus and down 3.8% sequentially. Phosphorodiamidate morpholino oligomer (PMO) products generated US$230.6 million, 0.7% below the US$232.2 million consensus and up just 0.9% quarter over quarter after an 11.8% decline in 1Q26. Management narrowed 2026 product revenue guidance to US$1.2-1.3 billion, expects second-half product revenue below first-half levels, and guided 3Q26 ELEVIDYS revenue below 2Q26 levels. Despite that trajectory, shares rose only as much as approximately 2.5% after hours.

The analysts inferred that the market is assigning significant value to SRP-1001 and SRP-1003, "even though the evidence remains concentrated in delivery, exposure, early target engagement, and safety." They identified the 2H26 myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD) multiple ascending dose (MAD) updates as the next potential stock value inflection points, followed by ELEVIDYS Cohort 8 data in 1Q27.

Fifth Consecutive ELEVIDYS Decline, With a Sixth Guided

ELEVIDYS revenue fell to US$98.1 million from US$102.0 million in 1Q26, US$110.4 million in 4Q25, US$132.0 million in 3Q25, US$282.0 million in 2Q25, and US$375.0 million in 1Q25. Current 3Q26 consensus of US$101.8 million assumes approximately 3.8% sequential growth, which the analysts said needs to move lower given management's guidance for another decline. At the US$1.25 billion midpoint of guidance, 2H26 product revenue would be approximately US$591 million versus US$659 million in 1H26, a roughly 10% half-over-half decline.

Management cited record healthcare-provider engagement, a majority of 2Q26 enrollment forms linked to providers engaged within the preceding 90 days, and increased activity from new and returning sites. The company still applies a roughly six-month enrollment-form-to-infusion planning assumption and indicated that recent enrollment gains should contribute primarily to 2027. Management declined to provide 2027 sales guidance. The analysts noted their benchmark remains completed infusions and recognized revenue, adding that "enrollment forms are early-funnel activity and do not support higher estimates" absent evidence that patients progress through authorization, scheduling, and infusion.

PMO Franchise Stabilizes but Faces 2027 Pressure

The 2Q26 PMO revenue of US$230.6 million was approximately 11% below the US$259.2 million generated in 4Q25. EXONDYS generated US$119.8 million, AMONDYS generated US$76.7 million, and VYONDYS generated US$34.0 million. Management cited adherence above 90%, more than 1,800 treated patients, extensive real-world experience, and an established reimbursement infrastructure as support for durability, while acknowledging incoming exon-skipping competition with commercial effects expected to become more visible later in 2027. Current 3Q26 consensus of US$235.4 million assumes approximately 2.1% sequential growth; the analysts do not believe the franchise can return to sustained growth.

The February 28, 2027, FDA target date for the AMONDYS and VYONDYS traditional approval conversions could protect the PMO cash-flow floor, though the applications remain dependent on a failed randomized primary analysis. The ESSENCE study enrolled 225 patients with DMD amenable to exon 45 or exon 53 skipping and missed its Week 96 four-step ascend velocity primary endpoint, with a least-squares mean treatment difference of 0.06 steps/second and p=0.309. An analysis excluding 23 patients affected by COVID improved the difference to 0.12 steps/second with p=0.050. Management said the reviews are standard and the agency has not indicated plans for an advisory committee, though the analysts cautioned that filing acceptance establishes a review timetable without establishing the sufficiency of the efficacy package.

DM1 and FSHD Programs Show Delivery Advantage but Incomplete Translation

SRP-1003 previously showed muscle concentration of 12.2nM versus approximately 1.43nM for the del-desiran program of Novartis AG (NVS:NYSE)/Avidity Biosciences and approximately 1.86nM for z-basivarsen from Dyne Therapeutics Inc. (DYN:NASDAQ). Sarepta disclosed placebo-adjusted DMPK knockdown of just over 50% in Cohort 1 but lacked Cohort 2 and Cohort 3 results due to sample-availability and assay-transition issues. Lower muscle concentrations have already produced downstream and functional signals elsewhere: Novartis/Avidity reported approximately 47% DMPK reduction and roughly two- to three-second video hand-opening time (vHOT) improvement at one year, while Dyne reported approximately 26% knockdown and a 3.3-second vHOT improvement at six months sustained at one year. The 2H26 update is expected to include safety, serum and muscle pharmacokinetics, DMPK knockdown, CASI-22 splicing, and vHOT analyses.

SRP-1001 previously showed 28.4nM muscle concentration, approximately 90% placebo-adjusted suppression across pooled DUX4-regulated gene panels, and a 33% creatine kinase reduction — only modestly above the approximately 30% reduction previously reported by Avidity. The lower cohorts were pooled, and assay dropout limited interpretation. Management said the six-month MAD update is intended to establish the chain from muscle exposure to DUX4-related biomarkers and select a dose, but does not expect the dataset to definitively demonstrate functional benefit given slow FSHD progression and short follow-up. Meanwhile, the Novartis del-desiran Phase 3 HARBOR DM1 readout is expected in 2H26, Novartis/Avidity's del-brax has entered Phase 3 FSHD development after its FORTITUDE biomarker cohort met primary and key secondary endpoints, and Dyne has cleared an FSHD Investigational New Drug application. License economics also share success through future milestones, royalties reaching the low double digits, and a US$50 million annual collaboration fee included in 2026 non-GAAP expense guidance.

Cash Generation Funds Upcoming Readouts

Total revenue was US$401.3 million, including US$328.7 million of product revenue and US$72.6 million of collaboration and other revenue. Cash and investments rose to US$945 million from approximately US$748 million sequentially, an increase of US$197 million that included receipt of a US$40 million commercial milestone from Roche Holding AG (ROP.SW). Combined non-GAAP research and development and selling, general and administrative expenses were approximately US$165 million versus approximately US$224 million in 1Q26, and management tightened 2026 non-GAAP expense guidance to US$800-850 million from US$800-900 million. GAAP and non-GAAP operating income were US$13.3 million and US$86.5 million, respectively.

Valuation and Risks

The valuation is driven by a discounted cash flow assessment using a 12% discount rate and 2% terminal rate of decline. The analysts made no changes to estimates, probability of approval, rating, or price target, noting the quarter supports their expectation that marketed DMD revenue will continue to fall while the 2H26 DM1/FSHD updates remain the primary source of potential value beyond cash generation.

Risks to price target achievement include a faster ELEVIDYS demand recovery, PMO traditional approvals, and slower competitive erosion, Cohort 8 data supporting nonambulatory re-entry with payer adoption, a favorable sirolimus package enabling SRP-9003 Biologics License Application progress, and stronger-than-expected DM1/FSHD dose-response, biomarker, or functional data. Downside risks include continued ELEVIDYS underutilization, additional safety events, payer resistance, further PMO erosion, or placebo-controlled data that weaken confidence in ELEVIDYS efficacy.

Sarepta shares traded at US$15.93 as of the August 5, 2026, close, within a 52-week range of US$14.68 to US$25.32, with a market capitalization of approximately US$1.68 billion, an enterprise value of approximately US$1.58 billion, and 105.6 million shares outstanding. The US$5.00 price target implies approximately 69% downside from that level.

Important Disclosures:

This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Sarepta Therapeutics Inc., August 6, 2026

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility. RETURN ASSESSMENT Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector. Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector. Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector.

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months. Distribution of Ratings Table as of August 5, 2026 IB Service/Past 12 Months Ratings Count Percent Count Percent Buy 531 83.75% 157 29.57% Neutral 49 7.73% 11 22.45% Sell 2 0.32% 0 0.00% Under Review 52 8.20% 22 42.31% H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Mitchell S. Kapoor, MBA, MS and Raghuram Selvaraju, Ph.D., MBA, MS , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Sarepta Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of July 31, 2026 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Sarepta Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Sarepta Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Sarepta Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: SRPT:NASDAQ, )

AI Cancer Drug Developer Advances Pipeline as Funding Expands

Thu, 13 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/13/2026

Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing in vivo testing and AI-driven lead optimization across its cancer drug pipeline as it expands relationships with AI companies and pursues additional non-dilutive funding.

Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and continuing AI-driven lead optimization through its collaboration with Variational AI, while enhancing relationships with AI companies and seeking non-dilutive financing from government and industry sources.

The work is being supported by Rakovina's non-brokered private placement, which the company increased from CA$1.5 million to up to CA$2 million following what it described as strong investor demand. The first tranche consisted of 13,940,000 units priced at CA$0.10 per unit for aggregate gross proceeds of CA$1.394 million. The offering was initially announced July 15 and was extended by 30 days to September 10.

Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at an exercise price of CA$0.20 per share for 24 months from the date of issuance.

In connection with the first tranche, Rakovina paid aggregate cash finder's fees of CA$85,315 and issued 853,150 finder's units to arm's-length finders. Each finder's unit allows the holder to acquire one share at CA$0.10 and one-half of one share purchase warrant. Each whole warrant is exercisable for one additional share at CA$0.20 for 24 months from the date of issuance.

Company insiders purchased an aggregate of 1.9 million units in the first tranche for gross proceeds of CA$190,000. Participants included Chief Executive Officer and Director Kim Oishi, whose subscription was made through First Growth Equity Partners Inc., and Chief Financial Officer and Director David Kideckel. Units issued to insiders are subject to a four-month-and-one-day hold period under applicable TSX Venture Exchange policies.

The company said proceeds from the offering would be used to advance its pipeline, primarily through in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and continued AI-driven lead optimization through its collaboration with Variational AI. Funds will also support the kt-3000 LNP formulation program, ongoing kt-2000AI compound development, and general working capital.

"We are encouraged by the strong support we've received from both existing shareholders and new investors," Oishi said in the company news release. "Increasing the size of this financing positions us to build on our scientific momentum and execute on important milestones ahead as we work to deliver transformational therapies for patients."

Oishi also said the company was enhancing its relationships with AI companies involved in its drug discovery and development work and seeking non-dilutive financing from government and industry sources.

The offering remains subject to customary closing conditions, including approval by the TSX Venture Exchange. Rakovina said it expected to close one or more additional tranches. Securities issued under the offering are subject to a four-month-and-one-day hold period from the closing date, in addition to other restrictions under applicable law.

Targeted Cancer Therapies Advance Alongside Growing Oncology Drug Market

According to a July report from Roots Analysis, the global cancer metabolism-based therapeutics market was valued at US$2.7 billion in 2025 and US$3.7 billion in 2026. The report identified small molecules as the modality holding the largest share of the market in 2026, while North America accounted for more than 50% of the market.

According to an industry report from Allied Market Research, the top 10 cancer drugs market had been valued at US$77.9 billion in 2022 and was estimated to reach US$198.8 billion by 2032, representing a compound annual growth rate of 10% from 2023 through 2032. The report attributed market expansion to rising cancer prevalence, growth in the elderly population, and greater cancer awareness.

Allied Market Research said increased oncology and molecular biology research had produced "a better understanding of cancer biology," which had supported the development of more targeted and effective cancer drugs. The report also said technological advances in genomics, proteomics, and high-throughput screening had accelerated cancer drug discovery and development by helping researchers identify potential drug targets and design treatments.

The report identified personalized medicine as another area of oncology drug development, describing it as an approach that involved "tailoring treatments to an individual patient's unique genetic and molecular profile." It said this approach had contributed to targeted therapies designed around genetic alterations associated with individual cancers and stated that these therapies "tend to be more effective and have fewer side effects as compared to traditional chemotherapy."

Allied Market Research also reported that an increase in pipeline drugs had broadened the range of mechanisms of action, molecular targets, and administration methods under development. It said new pipeline drugs "often represent latest advancements in cancer research and therapeutic innovation" and could involve new ways of targeting cancer cells or supporting immune responses against cancer.

A cancer metabolism-based therapeutics report last updated in July described a market valued at US$2.7 billion in 2025 and US$3.7 billion in 2026. The report estimated a compound annual growth rate of 24.3% from 2026 through 2035 and identified small molecules as the modality expected to account for the largest market share in 2026.

An August 12 report from Market.us Media provided additional context on the broader oncology care environment. It cited World Health Organization estimates that approximately 20 million new cancer cases had been reported globally in 2022 and that annual cases were projected to exceed 35 million by 2050, representing an increase of about 77%.

Market.us Media said the growing cancer burden had been associated with population aging, population growth, and risk factors including tobacco use, alcohol consumption, obesity, and air pollution. The report also noted that cancer prevalence had increased with age and that the global population age 60 and older had been projected to rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050.

The report highlighted the clinical complexity associated with cancer treatment, stating that cancer patients had frequently experienced nutrition-related problems, including appetite loss, weight decline, and cachexia. It cited National Cancer Institute figures indicating that malnutrition had affected approximately 30% to 85% of cancer patients, depending on cancer type, disease stage, and treatment setting.

Market.us Media said the oncology care sector had increasingly incorporated specialized support around cancer treatment and recovery. It reported that healthcare systems had focused on interventions supporting "muscle preservation, immune function, treatment tolerance, and recovery among elderly patients," reflecting the broader range of clinical needs surrounding cancer therapy.

Pipeline Work Extends Through 2026 and Into 2027

Rakovina's May investor presentation outlined work across three drug programs, kt-5000AI, kt-3000, and kt-2000AI. Milestones scheduled for the first and second quarters of 2026 have been excluded here because those periods had already passed by the August 13 publication date.

For kt-5000AI, the company's dual ATR/mTOR inhibitor program, the presentation identified in vivo ADME and efficacy work and advancing lead candidate selection during the third quarter. The August financing announcement also identified in vivo ADME and efficacy testing as a primary use of proceeds, along with continued AI-driven lead optimization through the company's collaboration with Variational AI.

The May presentation described kt-5000AI as a dual ATR/mTOR inhibitor designed for central nervous system (CNS) penetration for solid tumors, PTEN-deficient cancers and CNS metastases. It stated that 138 molecules had been predicted, 43 had been synthesized, and leads had been confirmed as potent and selective. CNS penetration and tolerability had also been confirmed in vivo. The presentation identified lead-optimization results from the expanded AI collaboration and lead selection among the program's 2026 milestones, along with in vivo model data at peer-reviewed meetings and ongoing partner discussions.

Additional optimization work was also identified in the presentation's April 2026 kt-5000AI poster data. The material stated that candidate inhibitors showed varying levels of CNS penetrance, activity, and metabolic stability broadly consistent with AI predictions and that further optimization was ongoing.

For the fourth quarter, Rakovina's May presentation identified the selection of a kt-5000AI lead. The company's timeline then listed GLP toxicology and IND-enabling studies for the ATR/mTOR program during the first half of 2027.

The kt-3000 program was also scheduled for additional work during the remainder of 2026. Rakovina described kt-3000 as a dual PARP/HDAC inhibitor for PARP-resistant adult and childhood cancers, including Ewing sarcoma. The program included a NanoPalm joint venture combining Rakovina's AI drug discovery work with NanoPalm's self-targeting patterned lipid nanoparticle delivery system, with Rakovina retaining intellectual property rights.

The presentation scheduled continued in vivo studies for the PARP/HDAC program during the third quarter. It separately identified JV funding, an ADC partnership and nano-lipid formulation data at peer-reviewed meetings among its 2026 milestones. The August financing announcement stated that proceeds would support the advancement of the kt-3000 LNP formulation program.

The presentation's April 2026 kt-3283 LNP poster data stated that further development included in vitro and in vivo characterization to confirm the activity of pLNP-kt-3283 against PARP and HDAC enzymes, determine ADME properties, and determine efficacy against in vivo tumor models. The company's timeline identified GLP toxicology and IND-enabling studies for the PARP/HDAC program during the first half of 2027.

Rakovina's third program, kt-2000AI, uses the deep docking platform and is directed toward breast, ovarian, and prostate cancers. The presentation stated that billions of compounds had been screened through deep docking, 389 compounds had been assessed against PARP, and leads had been confirmed with PARP selectivity and drug-like properties.

The August financing announcement identified ongoing kt-2000AI compound development as another use of proceeds. For the fourth quarter, the May presentation scheduled another round of AI output for the PARP program, with lead candidate selection advancing. PARP program lead selection was listed for the first half of 2027.

At the corporate level, the May presentation scheduled the finalization of a Saudi joint venture during the third quarter. Its fourth-quarter milestones included securing institutional funding and participation in SNO, AACR-NCI-EORTC, and BIO Middle East conferences. For the first half of 2027, the presentation identified the development of strategic pharmaceutical partnerships. [OWNERSHIP_CHART-11193]

The more recent August financing announcement also stated that Rakovina was seeking non-dilutive financing from government and industry sources while enhancing relationships with AI companies involved in drug discovery and development. The immediate financing timeline extends through September 10, the new closing date for the expanded private placement, with the company expecting to close one or more additional tranches.

Ownership and Share Structure¹

Edison Oncology holds approximately 9.9% of Rakovina Therapeutics. Management and reporting insiders account for about 9.64% ownership, with the remainder held by a combination of institutional, retail, and other investors, as previously disclosed in company materials.

Rakovina completed a 10-to-1 share consolidation in June 2025, with shareholders receiving one post-consolidation common share for every ten previously held.

As of August 13, 2026, Rakovina Therapeutics had approximately 38.35 million issued and outstanding shares. At a recent trading price of approximately CA$0.13 per share, the company's market capitalization was approximately CA$5.0 million. Its 52-week trading range was approximately CA$0.09 to CA$0.84 per share.

FAQs

What did Rakovina Therapeutics announce in August 2026?

Rakovina Therapeutics Inc. announced that it closed the first tranche of its non-brokered private placement, issuing 13.94 million units at US$0.10 per unit for aggregate gross proceeds of US$1.394 million. The company also increased the offering from US$1.5 million to up to US$2 million and extended it to September 10.

Why did Rakovina Therapeutics increase the size of its private placement?

Rakovina Therapeutics said it increased the financing from US$1.5 million to up to US$2 million due to strong investor demand. The offering was originally announced on July 15.

How will Rakovina Therapeutics use the private placement proceeds?

Rakovina said proceeds would primarily support in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and continued AI-driven lead optimization through its collaboration with Variational AI. Funding will also support the kt-3000 LNP formulation program, ongoing kt-2000AI compound development, and general working capital.

What is Rakovina Therapeutics' kt-5000AI cancer drug program?

Rakovina described kt-5000AI as a dual ATR/mTOR inhibitor designed for CNS penetration and directed toward solid tumors, PTEN-deficient cancers and CNS metastases. Its May investor presentation stated that 138 molecules had been predicted, 43 had been synthesized, and leads had been confirmed as potent and selective.

What are the next milestones for Rakovina Therapeutics' kt-5000AI program?

Rakovina's May investor presentation identified in vivo ADME and efficacy work and advancing lead candidate selection during the third quarter of 2026. Lead selection was listed for the fourth quarter, followed by GLP toxicology and IND-enabling studies in the first half of 2027.

What is Rakovina Therapeutics' kt-3000 program?

The kt-3000 program involves a dual PARP/HDAC inhibitor for PARP-resistant adult and childhood cancers, including Ewing sarcoma. Rakovina's August financing announcement said proceeds would support the advancement of the kt-3000 LNP formulation program.

What is Rakovina Therapeutics' kt-2000AI program?

Rakovina described kt-2000AI as a PARP inhibitor program using its deep docking platform and directed toward breast, ovarian, and prostate cancers. The company's May presentation stated that billions of compounds had been screened, 389 compounds had been assessed against PARP, and leads had been confirmed with PARP selectivity and drug-like properties.

How does Rakovina Therapeutics use AI for cancer drug discovery?

Rakovina uses AI-powered drug discovery in developing its cancer therapy pipeline. Its programs included the Enki generative AI platform for kt-5000AI and the deep docking platform for kt-2000AI. The company also identified continued AI-driven lead optimization through its collaboration with Variational AI as a use of proceeds from its August financing.

How many shares does Rakovina Therapeutics have outstanding?

As of August 13, Rakovina Therapeutics had approximately 38.35 million issued and outstanding shares, based on the previously reported 24.41 million shares outstanding plus 13.94 million common shares issued in the first tranche of the private placement.

What is Rakovina Therapeutics' market capitalization and 52-week stock price range?

At a recent trading price of approximately CA$0.13 per share, Rakovina Therapeutics had an implied market capitalization of approximately CA$5.0 million as of August 13. Its 52-week trading range was approximately CA$0.09 to CA$0.84 per share.

Important Disclosures:

Rakovina has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RKV:TSX.V, )

Virtual Care Network Expands to Include 100,000 More New Yorkers, Reaching 24 Million Nationwide

Thu, 13 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/13/2026

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) recently added 100,000 eligible members in New York to its network. This expansion brings the total number of individuals with potential in-network access to the company's virtual care services to approximately 10 million in New York and 24 million across the United States.

Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) wholly owned subsidiary, Rocket Doctor Inc., expanded in-network access to physician-led virtual care in New York through a new agreement entered into by doctors using its digital health platform and marketplace.

The estimate excludes millions of members covered through administrative services only or self-insured plans. The payer also participates in a national reciprocal network program, allowing eligible out-of-state members to access Rocket Doctor's in-network physicians while traveling in New York.

With the latest agreement, Rocket Doctor has potential in-network access to approximately 10 million covered lives across New York and approximately 24 million covered lives across the United States through its network of commercial and public payer relationships.

The agreement was signed on July 15 and has an initial one-year term, with automatic one-year renewals unless terminated or non-renewed by either party in accordance with its terms.

Digital Health and AI Reshape Healthcare Delivery

The report described physician access as having become increasingly difficult as in-person access tightened and marketers shifted toward scalable digital channels. It cited industry benchmarks indicating that B2B email lists decayed at roughly 22.5% annually and said physician data could decay more quickly as doctors changed hospitals, completed residencies, and moved among healthcare systems.

Digital strategist Harsh Nigam described the consequences of inaccurate physician data in the report. "The real cost of bad data isn't the bounce, it's the physician, a competitor reached while your email went nowhere," Nigam said. "In healthcare, missed inboxes are missed prescribers."

The report also identified fragmentation as an issue in healthcare marketing, with data, email, search, and content sometimes handled separately. Harjyot Singh Isser said effective digital engagement required those functions to work together. "A verified physician database only pays off when the email, the content, the search visibility, and the targeting all move together," Isser said.

D'Incerti said AI initiatives had encountered similar considerations as healthcare organizations evaluated platforms, governance, and regulatory compliance. "The bigger challenge is helping people understand how AI fits within daily work, building trust, and integrating it into workflows," she wrote. "In other words, the challenge is not simply technological. It is organizational."

She also emphasized clinician participation in technology adoption, noting that healthcare professionals had expressed concerns involving transparency, reliability, accountability, and workflow effects. "Adoption cannot be mandated. It must be earned," D'Incerti wrote.

Workflow integration was another factor identified in the article. D'Incerti wrote that healthcare organizations had previously found that technology by itself did not improve outcomes and that benefits emerged when technology corresponded with clinical workflows. "The most successful AI deployments are those that integrate into existing environments, support decision-making, and eliminate administrative burden instead of adding complexity," she wrote.

Trust also remained an important consideration because healthcare technology affected care outcomes, regulatory compliance, and organizational performance. D'Incerti said clinicians and staff expected transparency about how technologies functioned and how recommendations were generated. She concluded that healthcare's earlier digital transformations had demonstrated the importance of clinician engagement, workflow alignment, leadership commitment, workforce readiness, and organizational trust.

Technical Analyst Rated Rocket Doctor AI a Strong Speculative Buy

Addressing the company's U.S. operations, Thomson cited its technology, payer contracts, physician credentialing, and revenue operations. He wrote that competitors faced "a minimum of 18 to 24+ months to replicate the position Rocket Doctor AI is in today."

Thomson established three technical price targets for the shares: CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term.

Payer Expansion, Physician Credentialing, and AI Development Remain on the Agenda

Rocket Doctor AI's August investor overview identified additional state expansion, physician credentialing, and development of its healthcare AI products among the company's ongoing programs.

The company's U.S. payer approach covers channels including: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits, and commercial insurance, and out-of-network patients. The presentation stated that each payer relationship could provide indicative potential access to 1 million to 2 million or more covered lives.

Rocket Doctor AI's Global Library of Medicine (GLM) has been in development since 2016, with more than 25,000 hours of input from hundreds of clinicians globally and approximately 10,000 or more expert medical reviews. The GLM includes more than 1,000 diseases and 17,000 symptoms in real time and suggests appropriate lab tests and imaging, treatment options, and billing codes. The company also described plug-and-play API integration for connecting the system to other platforms, such as EMR’s, AI Scribes, and or other healthcare systems offering patient-facing services.

Ownership and Share Structure²

As of August 13, 2026, Insider ownership of Rocket Doctor AI totals 4.24%. Retail investors hold the rest.

Frequently Asked Questions About Rocket Doctor AI

What is Rocket Doctor AI Inc.?

Rocket Doctor AI Inc. provides a suite of healthcare technology. Through its wholly owned subsidiary, Rocket Doctor Inc., its operations include a digital health platform and marketplace, virtual physician care, and healthcare AI tools designed to support providers across the care process.

What did Rocket Doctor AI announce about its access to New York healthcare network?

Rocket Doctor announced an agreement expanding potential in-network access to physician-led virtual care for a further 100,000+ additional eligible covered lives across participating individual Medicare Advantage PPO and commercial health plans in the New York metropolitan region and select upstate counties.

How many covered lives does Rocket Doctor have access to in New York and the United States?

Following the latest agreement, Rocket Doctor said it has potential in-network access to approximately 10 million covered lives across New York and approximately 24 million covered lives across the United States through its network of commercial and public payer relationships.

When did Rocket Doctor sign its latest New York health plan agreement?

The agreement was signed on July 15. It has an initial one-year term and automatically renews for additional one-year periods unless either party terminates or does not renew it in accordance with the agreement's terms.

What healthcare services does Rocket Doctor provide through its virtual care platform?

Rocket Doctor's programs connect patients with licensed physicians from home for services that include urgent care, chronic disease management, preventive health, pediatrics, and mental health support.

Can patients use health insurance to access Rocket Doctor physicians?

Eligible members covered by participating health plans can access Rocket Doctor's in-network physician services through their existing insurance coverage. There is also scope for private pay.

Can out-of-state patients access Rocket Doctor physicians while visiting New York?

The payer involved in Rocket Doctor's latest agreement participates in a national reciprocal network program. This facilitates eligible out-of-state members to access Rocket Doctor's in-network physicians while traveling in New York.

How is Rocket Doctor AI using artificial intelligence in healthcare?

Rocket Doctor AI is using AI in the development of its solutions, and in particular, healthcare technology includes AI-assisted intake, AI-driven diagnostic support, smart triage, doctor and patient matching, an AI Assistant, AI Scribe, and AI-supported follow-up functions. Its platform also includes the Global Library of Medicine. It’s important to note that all of the technology is validated through physician groups for accuracy before being released.

What is Rocket Doctor AI's Global Library of Medicine?

The Global Library of Medicine, or GLM, has been developed since 2016 with more than 25,000 hours of input from hundreds of clinicians globally and approximately 10,000 or more expert medical reviews. According to the company's investor overview, it covers more than 1,000 diseases and 17,000 symptoms in real time and can suggest appropriate lab tests and imaging, treatment options, and billing codes.

How many physicians are active or credentialed with Rocket Doctor in the United States?

Rocket Doctor AI's August investor overview reported 22 clinically active U.S. physicians and another 33 physicians undergoing credentialing.

How many U.S. patient visits has Rocket Doctor reported?

The company's investor overview showed completed U.S. patient visits increasing from 86 in December 2025 to 177 in January, 464 in February, 678 in March, and 1,144 in April.

What U.S. health insurance markets is Rocket Doctor targeting?

Rocket Doctor AI's investor overview identified four primary channels in its U.S. payer approach: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits, and commercial insurance, and out-of-network care.

Where is Rocket Doctor planning additional U.S. healthcare expansion?

The company's August investor overview identified Florida and Texas among its state expansion pipeline and listed extending existing relationships with payers as its strategy.

What rating did technical analyst Stewart Thomson give Rocket Doctor AI stock?

In a March 17 report, technical analyst Stewart Thomson assigned Rocket Doctor AI a Strong Speculative Buy technical rating.

What were Stewart Thomson's price targets for Rocket Doctor AI stock?

Thomson set technical price targets of CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term.

Important Disclosures:

Rocket Doctor is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%

Wed, 12 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/12/2026

DarioHealth reported Q2 revenue of $5.2 million with gross margin rising to 62 percent and contracted ARR reaching $13.1 million after signing a fifth Fortune 50 client and expanding provider-backed care.

Retail investors tracking the digital health sector are focusing on DarioHealth Corp. (DRIO:NASDAQ) after the company delivered its Q2 2026 results. The firm operates an AI-powered platform that helps users manage multiple chronic conditions through connected devices and data analytics.

Workplace Health Trends Fuel Demand for Scalable Digital Solutions

Employers face rising costs from chronic illness and behavioral health issues that reduce productivity. Studies link workplace stressors to higher rates of cardiovascular disease, diabetes, and mental health conditions. One analysis estimates that 5 to 8 percent of U.S. healthcare spending stems from job-related stress, while another places annual lost productivity costs at roughly $575 billion. These pressures encourage companies to adopt digital tools that improve employee outcomes without adding large overhead.

Why DarioHealth Stands Out in the AI Healthcare Space

DarioHealth differentiates itself with a vertically integrated platform that combines FDA-cleared devices, longitudinal data, and its proprietary DarioIQ AI engine. The system supports more than six chronic conditions and delivers personalized interventions. Recent extensions into provider-backed care through a partnership with Beluga Health add clinical services across all 50 states, moving beyond purely digital engagement. New offerings such as Dario Women for menopause-related health risks and Dario Sleep for apnea further broaden the addressable market.

Commercial Momentum and Multi-Condition Adoption

The company signed its fifth Fortune 50 client, covering more than 100,000 eligible employees, with annual recurring revenue expected to begin contributing late in 2026. A new health insurer partnership via the Amwell channel adds hundreds of thousands of potential users. An existing top-five national health plan extended its behavioral health contract and added hypertension management, a change that could triple revenue from that account. Solera expanded its hypertension program, adding at least 500,000 more eligible individuals. More than 80 percent of the $13.1 million in contracted and late-stage annual recurring revenue now comes from multi-condition deals.

Financial Efficiency Improves Alongside Growth

Revenue reached $5.2 million in Q2 2026. Gross margin climbed to 62 percent from 55 percent a year earlier, while non-GAAP B2B2C margins held near 80 percent. Operating expenses fell 21 percent year over year, narrowing the operating loss by 30 percent. Pro forma cash, cash equivalents, and short-term deposits rose to $36.8 million after a July financing that raised $23.5 million in gross proceeds. Financial and commercial results show these efficiency gains occurred while the company deployed AI tools internally to control costs.

Analyst Perspective and Valuation Context

ThinkEquity analyst Ashok Kumar reiterated a Buy rating and raised the price target to $12. The upgrade cited sequential B2B2C growth, timely Fortune 50 activations, channel execution, and margin expansion toward the mid-60 percent range. The firm noted that visible commercial conversion and disciplined cash use would further support the thesis.

Key Investor Takeaways

Contracted and late-stage ARR reached $13.1 million, with over 80 percent from multi-condition offerings that improve customer retention.
Gross margin expanded to 62 percent while operating expenses declined 21 percent year over year, demonstrating operating leverage.
New wins include a fifth Fortune 50 client and a major health insurer via Amwell, expanding the total addressable population.
Provider-backed care through Beluga Health adds 50-state clinical delivery and opens additional revenue streams.
Pro forma cash stands at $36.8 million after the July financing, providing runway for commercial execution.
DarioIQ AI deployment is expected to lift B2B2C ARR from existing customers by 10 to 15 percent through better engagement.

Ownership Structure and Share Information

DarioHealth Corp. has a market capitalization of approximately $75 million with 9.79 million shares outstanding. The 52-week trading range spans $5.84 to $17.74. ¹Institutions hold 9.18 percent, strategic investors 7.37 percent, and management plus insiders 8.52 percent, leaving retail investors with the balance.[OWNERSHIP_CHART-9981]

Common Questions from Investors

Q: What does B2B2C mean in this context?
A: B2B2C refers to a business-to-business-to-consumer model where DarioHealth supplies its platform to employers or health plans that then offer it to their members or employees.

Q: How does annual recurring revenue differ from reported quarterly revenue?
A: Annual recurring revenue measures the annualized value of contracted subscriptions, providing a forward-looking view of predictable income, whereas quarterly revenue reflects actual recognized amounts in a given period.

Q: What is provider-backed care, and why does it matter?
A: Provider-backed care integrates digital tools with licensed clinical services. The Beluga Health partnership gives DarioHealth embedded clinical delivery in all 50 states, allowing it to capture more of the care value chain.

Q: Why did gross margin improve?
A: Higher-margin B2B2C revenue and operational efficiencies, including AI-driven internal processes, lifted gross margin to 62 percent from 55 percent year over year.

Investors should weigh these developments against typical risks in early-stage digital health companies, including customer concentration, competition, and the need for continued commercial execution.

[SMNLINSERT]

Important Disclosures:

DarioHealth Corp. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: DRIO:NASDAQ, )

The Life Sciences Report

Rocket Doctor AI Secures California Network Deal Reaching 60M Consumers

Why the California Agreement Matters Now

Company Advantage Through Diversified Access

Key Assets and Near-Term Catalysts

Broader Telehealth Sector Timing

Analyst Views and Valuation Context

Share Structure and Liquidity2

Key Investor Takeaways

Common Questions from Investors

Rocket Doctor AI Signs Strategic Network Agreement to Expand California Reimbursement Access

Telehealth Market Expanding Rapidly

Analysts See Momentum, Reiterate Bullish Ratings

Catalysts Include State Expansion, Rising Patient Volumes, and AI Tool

Ownership & Share Information2

Frequently Asked Questions

Cleantech Developer Advances Five Platforms With 26% Revenue Growth

Why BioLargo's Funding Approach Matters to Investors

Key Investor Takeaways

Unique Business Model Spreads Risk Across Platforms

Medical and Consumer Platforms Nearing Commercial Milestones

Water Treatment, Engineering, and Energy Storage Advance Through Alliances

Industry Trends Support Multiple Addressable Markets

Analyst Perspectives Highlight Partnership Strategy

Share Structure and Upcoming Events2

Common Questions from Investors

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline

Market Opportunity in Rare Genetic Diseases

Why Sarepta Therapeutics Stands Out Now

Key Investor Takeaways

Financial Performance and Business Model

Leadership Transition and Pipeline Catalysts

Analyst Views and Valuation Context

Upcoming Pipeline Milestones

Share Structure and Ownership Details1

Common Questions from Investors

DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances

The Expanding Opportunity in DMD Therapeutics

Key Investor Takeaways

Why Satellos Stands Out in Muscle Regeneration

Clinical Pipeline and Near-Term Catalysts

Financial Position and Operating Results

Views and Valuation Context

Share Structure and Upcoming Events1

Common Questions from Investors

Cleantech Firm Raises 86% of Capital Without Selling Stock

Clyra and ViaCLYR™ Leading the Way

Expert: Portfolio Spans Several Cleantech Categories

Catalysts: Addressing Growing Markets

Ownership and Share Structure2

Common Investor Questions

Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M

Key Takeaways

Satellos Targets Degenerative Muscle Diseases

DMD Market Seen Growing at 30.5% CAGR

Chen Lin Sees 10x Potential

FSHD IND Filing Coming Soon

Ownership & Share Information1

Frequently Asked Questions

Sarepta Posts US$328.7M Results

Key Takeaways

New CEO, Narrowed Revenue Guidance

DMD Market Growing Fast

Is the Stock a Hold?

Huntington's Program Begins Phase 1 Dosing

Ownership & Share Information1

Frequently Asked Questions

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

Healthcare AI Market Expands as Providers Adopt Workflow Tools

Key Investor Takeaways

Why Doximity Stands Out in Digital Health

Financial Results Show Revenue Growth With Margin Pressure

AI Suite and Engagement Metrics Provide Growth Catalysts

Analyst Views and Price Targets Reflect Divergent Outlooks

Guidance and Commercial Reach Set Near-Term Milestones

Ownership and Share Structure1

Common Questions from Investors

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

AI Moves Deeper Into Healthcare Workflows as Digital Health Adoption Expands

Third-Party Expert Analysis: Analysts Set Targets

Share Structure and Liquidity²

Ownership & Share Information²

Share Structure and Upcoming Events²

Share Structure and Ownership Details¹

Share Structure and Upcoming Events¹

Ownership and Share Structure²

Ownership & Share Information¹

Ownership & Share Information¹

Ownership and Share Structure¹

Ownership and Share Structure¹

Ownership and Share Structure¹

Ownership and Share Structure²